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Abstract 
 
A Western diet is characterized by several components, but the main traits are a substantial 
consumption of red meats, refined carbohydrates and saturated fatty acids. Poor dietary 
choices and a low level of physical activity can quickly lead to lifestyle diseases like obesity and 
metabolic syndrome. It has previously been shown that the macronutrient composition of the 
diet affects the low-grade systemic inflammation in obese men. Both metabolic syndrome and 
obesity is linked to hyperinsulinemia and insulin resistance. Insulin signals through the insulin 
receptor (IR), which subsequently leads to many cellular responses including the activation of 
nuclear factor-κB (NF- κB) and induction of pro-inflammatory mediator production. Increasing 
body mass index has been linked to increasing disease activity scores (DAS28) for Rheumatoid 
Arthritis (RA) patients. RA is an autoimmune disease of the synovial membrane of joints, which 
becomes a hyperplastic, invasive tissue teeming with immunocompetent cells. This will 
eventually lead to excessive bone loss and chronic inflammation of the synovial membrane, a 
condition called synovitis.  
 
The effect of chronic elevated levels of insulin on disease activity of RA is not yet known. Here, 
we investigate the potential of insulin to activate cytosolic phospholipase A2α (cPLA2α), which 
has been shown to be a key regulator of inflammation in RA, in a cell model for synovitis 
(SW982). In this master’s thesis we also investigate a potential role for insulin in regulating 
proliferation and gene expression in SW982. More specifically, the time-dependent regulation of 
the genes insulin receptor (IR), insulin-like growth factor 1 receptor (IGF1R), c-Myc, c-Fos and 
interleukin 6 (IL-6) was investigated.  
 
Detection of IR and IGF1R expression by real time quantitative polymerase chain reaction (RT-
qPCR) in SW982 synoviocytes, validated for the first time that these cells express the 
respective receptors and that they are potentially susceptible to insulin signaling. 
 
The activity of cPLA2α in response to insulin was evaluated using a radioactive release assay in 
pre-labeled SW982 cells, which measures the activity of cPLA2α by measuring the amount of 
arachidonic acid (AA) released from the cells. These tests showed that insulin did not increase 
the release of AA. However, this test did reveal a trend of decreased release of oleic acid (OA) 
in response to insulin. These results suggest a PLA2 independent pathway for insulin signaling. 
Also, a pro-inflammatory role of insulin mediated through the hormone sensitive lipase (HSL) is 
speculated upon based on these results. 
 
MTT viability assay was used to evaluate the effect of insulin on the metabolic activity of 
cultured SW982s. We found that insulin increases the metabolic activity by ~50% in a time, 
confluency and dose dependent manner. However, these results were not validated as 
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increased proliferation by flow cytometry. We speculate upon an activation of protein kinase B 
(PKB) by insulin, which signals increased survival of SW982 cells. 
 
By RT-qPCR we show that insulin downregulates IR expression, and a similar trend is observed 
for IGF1R. Insulin induced no change in c-Myc expression, and induced a downregulation of c-
fos after 12 hours. Further, insulin induced a time-dependent trend of increase in IL-6 gene 
expression. Insulin also induced variation in the expression of the previously accepted reference 
gene 18S. 
 
More tests have to be conducted in order to validate/discard the hypotheses proposed in this 
study. Including the possible pro-inflammatory actions of insulin in synovial cells and other 
tissue, mediated through inhibition of HSL. The potential for insulin to induce hyper proliferation 
and increased survival of synovial cells through activation of PKB, and the potential for insulin to 
induce expression proliferative and inflammatory genes. 
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Sammendrag 
 
En Vestlig diett karakteriseres gjerne ved flere komponenter, men i hovedtrekk domineres den 
av store mengder rødt kjøtt, raffinerte karbohydrater og mettet fett. Uheldige kostholdsvalg og et 
lavt nivå av fysisk aktivitet kan fort føre til livsstilssykdommer som overvekt og metabolsk 
syndrom. Det har tidligere blitt vist at kostholdets makronæringsstoffsammensetning påvirker 
den systemiske inflammasjonen hos overvektige menn. Både metabolsk syndrom og overvekt 
er forbundet med hyperinsulinemia og insulinresistens. Insulin signaliserer via insulinreseptoren 
(IR), som deretter fører til flere cellulære responser inkludert aktiveringen av transkripsjonsfaktor 
NF- κB (nuclear factor-κB) og induksjon av produksjon av pro-inflammatoriske mediatorer. Det 
har tidligere blitt vist at økende kroppsmasseindeks (BMI) sammenfaller med økende grad av 
sykdomsaktivitet (DAS28) hos pasienter med Revmatoid Artritt (RA). RA er en autoimmun 
sykdom i synovialmembranen i ledd, som blir til et hyperplastisk, invaderende vev som bugner 
av immunkompetente celler.  Dette vil til slutt føre til en høy grad av tap av ben og kronisk 
inflammasjon i synovialmembranen, en tilstand som kalles synovitt.  
 
Effekten av kronisk høye nivåer av insulin på sykdomsaktiviteten i RA er til nå uklar. I denne 
avhandlingen, utforsker vi insulins potensiale til å aktivere cytosolisk fosfolipase A2 (cPLA2α), 
som har blitt utpekt som en nøkkelregulator av inflammasjon i RA, i en cellemodell for synovitt 
(SW982). I denne avhandlingen utforsker vi også en potensiell rolle for insulin i reguleringen av 
proliferasjon og genuttrykk i SW982. Nærmere forklart, den tidsavhengige reguleringen av 
genene IR, insulin-liknende vekstfaktor 1 reseptor (IGF1R), c-Myc, c-Fos og interleukin 6 (IL-6). 
 
Deteksjon av IR og IGF1R ble utført ved hjelp av sanntids kvantitativ polymerase kjedereaksjon 
(RT-qPCR) i SW982 synoviocytter, som for første gang validerte at disse cellene uttrykker de 
respektive reseptorene og at cellene potensielt er mottagelige for insulinsignalisering.  
 
Aktiviteten til cPLA2α i respons til insulin ble evaluert ved hjelp av et radioaktivt frigjøringsforsøk 
i merkede SW982 celler, som måler aktiviteten av cPLA2α ved å måle mengden arakidonsyre 
(AA) som frigjøres fra cellene. Disse forsøkene viste at insulin ikke øker frigjøringen av AA. 
Men, disse testene avslørte en trend av reduksjon i frigjøringen av oljesyre (OA) i respons til 
insulin. Disse resultatene foreslår en PLA2-uavhengig signaliseringskaskade for insulin. Basert 
på disse resultatene, ble det også spekulert i en pro-inflammatorisk rolle for insulin mediert 
gjennom en hormonsensitiv lipase (HSL). 
 
MTT viabilitetsforsøk ble brukt til å evaluere effekten av insulin på metabolsk aktivitet hos 
kultiverte SW982. Vi observerte at insulin øker den metabolske aktiviteten med ~50% på en 
tids-, konfluens- og doseavhengig måte. Men, disse resultatene ble ikke validert som økt 
proliferasjon ved hjelp av flow cytometri. Likevel, spekulerer vi i en insulinavhengig aktivering av 
protein kinase B (PKB), som signaliserer til økt overlevelse i SW982. 
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Ved hjelp av RT-qPCR har vi vist at insulin nedregulerer uttrykket av IR, og at en liknende trend 
observeres for IGF1R. Insulin induserer ingen endring i uttrykk av c-Myc, og induserer en 
nedregulering av c-Fos etter 12 timer. Videre, insulin induserte en tidsavhengig trend av 
oppregulering i uttrykket av IL-6. Insulin induserte også variasjon i uttrykket av det etablerte 
referansegenet 18S. 
 
Flere tester må utføres for å kunne bekrefte/avkrefte hypotesene i denne avhandlingen. 
Inkludert en mulig pro-inflammatorisk effekt av insulin i synovialceller og andre vev, mediert av 
inhiberingen av HSL. Insulins potensiale til å indusere hyperproliferasjon og økt overlevelse hos 
synovialceller gjennom aktivering av PKB, og potensialet for insulin til å indusere uttrykk av 
proliferative og inflammatoriske gener.  
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List Of Abbreviations 
 
18S    Ribosomal 18S rRNA 
AA    Arachidonic Acid 
AATC    American Type Culture Collection 
AC    Adenylate Cyclase 
ALA    α-Linoleic Acid 
AP-1    Activating Protein 1 
ATP    Adenosine Triphosphate 
B2M    Beta-2 Microglobulin 
BEL    Bromoenol Lactone 
BMI    Body Mass Index 
BRC    Biological Resource Center 
C-Peptide   Connecting Peptide 
cAMP    Cyclic Adenosine Monophosphate  
CCP    Cyclic Citrullinated Peptides 
cDNA    Complimentary Deoxyribonucleic Acid 
cGMP    Cyclic Guanosine Monophosphate 
COX    Cutaneous Cyclooxygenase  
cPLA2α    Cytosolic Phospholipase A2 α 
Cq    Quantification Cycle 
CREBP    cAMP Response Element-Binding Protein 
Ct    Threshold Cycle 
CYP    Cytochrome P450 
DAMP    Damage Associated Molecular Pattern 
DAS28    Disease Activity Score, 28 Joints 
DCV    Dense Core Vesicle 
DGLA    Dihomo-gamma-linoleic Acid 
DHA    Docosahexaenoic Acid 
DHET    Dihydroxyeicosatrienoic Acid 
DMEM    Dulbecco’s Modified Eagle’s Medium 
DMEM10%   DMEM; 10% FBS, 3% Glutamine, 0.2% Gentamicin 
DMSO    Dimethyl Sulfoxide 
DNA    Deoxyribonucleic Acid 
ECM    Extra-Cellular Matrix 
EET    Epoxyeicosatrienoic Acid 
ELISA    Enzyme-Linked Immunosorbant Assay 
EPA    Eicosapentaenoic Acid 
ER    Endoplasmic Reticulum 
ETA    Eicotrioenic Acid 
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FBS    Fetal Bovine Serum 
fBSA    Fatty Acid Free Bovine Serum Albumin 
FLS    Fibroblast-Like Synoviocytes 
FSL-1    TLR-2/6 Ligand 
gDNA    Genomic Deoxyribonucleic Acid 
GLUT4    Glucose Transporter 4 
HDHA    Hydroxy-docosahexaenoic Acid 
HEPE    Hydroxyeicosapentaenoic Acid 
HETE    Hydroxyeicosatetraenoic Acid 
HETrE    Hydroxyeicosatrienoic Acid 
HODE    Hydroxyoctadecadienoic Acid 
HPRT    Hypoxanthine-Guanine Phosphoribosyltransferase 
HSC    Hematopoietic Stem Cells 
HSL    Hormone Sensitive Lipase 
ICAM    Intercellular Adhesion Molecule 
IFN- γ    Interferon-Gamma 
IGF1    Insulin-Like Growth Factor 1 
IGF1R    Insulin-Like Growth Factor 1 Receptor 
IKK    IKB Kinase 
IL    Interleukin 
iNOS    Nitric Oxide Synthase 
INS    Insulin 
iPLA2    Ca2+ independent PLA2 
IR    Insulin Receptors 
IRS1    Insulin Receptor Substrate 1 
LA    Linoleic Acid 
LDL    Low-Density Lipoprotein 
LOX    Lipoxygenase 
LT    Leukotriene 
LTA3    Leukotriene A3 
LTA4    Leukotriene A4 
LTB4    4-series Leukotrienes 
LXA4    Lipoxin A4 
Lyso-PC   Lyso-Phosphatidyl Choline 
MAFP    Methoxy Arachidonyl Fluorophosphate 
MAPK    Mitogen Activating Protein Kinase 
MHC    Major Histocompatibility Complex 
MMP3    Matrix Metalloproteinase 
mRNA    Messenger Ribo Nucleic Acid 
MTT    3,4,5 Dimethylthiazol-2,5 Diphenyl Tetrazolium 
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NaOH    Sodium Hydroxide 
NF-κB    Nuclear Transcription Factor 
NFATc1   Nuclear Factor of Activated T Cells 
NIDDM    Non-Insulin Dependent Diabetes Mellitus 
NIK    NFKB Inducing Kinase 
OA    Oleic Acid 
OD    Optical Density 
PACOCF3   Palmitoyl Trifluoromethyl Ketone 
PAF    Platelet Activating Factor 
Pam3CSK4   TLR2 Ligand 
PAMP    Pathogen Associated Molecular Pattern 
PC    Choline Phospholipids 
PCR    Polymerase Chain Reaction 
PD    Prostaglandin 
PDE3B    Phosphodiesterase 3B 
PDGF    Platelet Derived Growth Factor 
PDK1    Phosphoinositide-dependent Kinase 1  
PGD2    Prostaglandin D2 
PGE2    Prostaglandin E2 
PGF2    Prostaglandin F2 
PGF2a    Prostaglandin F2alpha 
PGI2    Prostaglandin I2 
PGJ2    Prostaglandin J2 
PGS    Terminal Prostanoid Synthase 
PI3K    Phosphoinositide 3-Kinase 
PIP2    Phosphatidylinositol-4,5-bisphosphate 
PIP3    Phosphatidylinositol-3,4,5-trisphosphate 
PKA    Protein Kinase A 
PKA    Protein Kinase A 
PKB    Protein Kinase B 
PKC    Protein Kinase C 
PKG    cGMP-dependent Protein Kinase 
PLC    Phospholipase C 
PTPN22   Protein Tyrosine Phosphatase, Non-Receptor Type 22 
PUFA    Poly-Unsaturated Fatty Acids 
QUEST-RA  Quantitative Patient Questionnaire Monitoring in Standard 
Clinical Care of Patients with RA 
RANK    Receptor Activator of NF-KB 
RANKL    Receptor Activator of NF-KB Ligand 
RER    Rough Endoplasmic Reticulum 
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RNA    Ribo Nucleic Acid 
ROS    Reactive Oxygen Species 
rRNA    ribosomal RNA 
RT-qPCR   Real Time Quantitative Polymerase Chain Reaction 
RvD    Resolvin D-series 
RvE    Resolvin E-series 
SF    Serum Free 
SF-DMEM   Serum free DMEM 
SLC2A4   Solute Carrier Family 2A4 
sPLA2    Secretory PLA2 
SW982    Human Synovial Cell Line 
TDMGlycerides   Tri-, di-, monoglycerides 
TGF    Transforming Growth Factor 
TGL    Triglyceride Lipase 
THP1    Human Leukemic Monocyte Cell Line 
TLR    Toll-Like Receptor 
Tm    Melting Temperature 
TNFα    Tumor Necrosis Factor Alpha 
TXB2    Series-2 Thromboxane 
WAT    White Adipose Tissue 
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1. Introduction 
1.1 The Western Diet 
A Western diet[1] is characterized by a substantial consumption of red meat, refined 
carbohydrates (with a high glycemic index) and saturated fatty acids, accompanied by the 
scarce content of micronutrients. The combination of a calorie dense diet and a sedentary life is 
a selling and effortless lifestyle among the urban population of the 21st century. The genetic 
makeup of humans determines the preferred way of living, which since the Paleolithic Era has 
been a pre-agricultural-revolution-lifestyle where the average Joe was a hunter-gatherer with 
significantly exceeding health markers, body composition and physical fitness compared to the 
modern average Joe[2]. The increasing interest for a western-type way of living was quickly 
accompanied by a series of illnesses commonly referred to as lifestyle diseases, also known as 
diseases of longevity or diseases of civilization. Lifestyle diseases may include several infamous 
conditions such as Alzheimer’s disease[3], asthma, some cancers[4], coronary heart disease[4], 
type 2 diabetes[5], metabolic syndrome[6] and obesity[6]. When living on a western diet, where 
carbohydrates with a high glycemic index vastly dominate the macronutrient composition, the 
body is forced to constantly produce and secrete the growth hormone insulin in order to cope 
with elevated levels of blood sugar.    
 
1.2 Insulin Resistance 
1.2.1 Insulin 
The primary structure of Insulin was elucidated in the mid 1950s by Fred Sanger, who later 
received the Nobel prize for his accomplishments.[7] Insulin is a two-chain, growth-promoting 
hormone[8], cleaved from a single-chain precursor. Initial translation of the insulin mRNA yields 
preproinsulin, which is a single polypeptide chain. Preproinsulin is cotranslationally translocated 
into the rough endoplasmic reticulum (RER), by the help of a 24-residue hydrophobic signal 
peptide at the N-terminal of the nascent chain.[7] Once inside the RER a peptidase will cleave 
the signal peptide to form the proinsulin, and chaperones will catalyze the folding of the 
hormone. After being folded, the proinsulin translocates to the Golgi, where it is transferred to 
immature secretory vesicles and subsequently cleaved into three fragments: connecting peptide 
(C-peptide), β-chain and α-chain (figure 1.2.1.1). In healthy individuals, insulin and C-peptide is 
secreted into the blood stream in equal amounts. Insulin hormone and connecting peptide is 
stored in dense core vesicles (DCVs) in the β-cells until the respective cell receives a signal to 
secrete the hormone.  
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Figure 1.2.1.1: The detailed structure of proinsulin. Contains C-peptide, β-chain and α-
chain.[9] 
 
 
1.2.2 Insulin Secretion 
When ingested, carbohydrates are dilapidated into sugar monomers (glucose), which reach 
cells throughout the body through the blood stream. Regardless of periods of feeding or fasting, 
plasma glucose levels in normal, healthy human beings remain in a range between 4 and 7 
mM.[10] The presence of glucose in the blood causes β-cells in the pancreas (islets of 
Langerhans) to secrete insulin. Insulin binds to the insulin receptor (IR), causing the cell to bring 
more glucose transporters to the surface, subsequently empowering the cell to lower blood 
sugar levels through the uptake of glucose. Insulin stimulates the translocation of the glucose 
transporter GLUT4 from intracellular sites to the cell membrane.[10] The GLUT4 protein is 
encoded by the Solute Carrier Family 2A4 (SLC2A4) gene, and is important for maintaining 
glycemic homeostasis.[11] Insulin signaling occurs through activation of its tyrosine kinase 
receptor, which subsequently activates the insulin receptor subunit 1 (IRS1), which in turn 
activates phosphoinositide 3-kinase (PI3K) resulting in the activation of several proteins, 
including protein kinase B (PKB). The activation of PKB can lead to a variety of cellular 
responses, including promotion of cell cycle, inhibition of apoptosis and cellular 
transformation.[12] Secretion of insulin also inhibits hepatic glucose production, lipolysis and 
protein breakdown, and activates several metabolic pathways, like glycogen synthesis, 
glycolysis, glucose oxidation, de novo lipogenesis and protein synthesis.[13] Insulin is the 
primary regulator of cell metabolism, but not the only. Insulin-Like Growth Factor 1 (IGF-1) is a 
polypeptide with similar structure and function as insulin.[14] IGF-1 is also an essential growth-
promoting peptide, and binds to the IGF1 Receptor (IGF1R). The binding affinity of IGF1 to 
IGF1R is high, likewise the binding affinity of insulin to IR is high. Even though these two growth 
hormones have their respective receptors, research suggests that they can bind to each other’s 
receptors (cross-binding).[14] The cross-binding affinity of the growth hormones to the receptors 
is not as high (1/1000), as the hormones binding to their specific receptor.[14] The IR is a 
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heterotetramer tyrosine kinase receptor, made of two α- and two β-chains linked by disulfide 
bonds. The IR is activated upon binding of an insulin ligand to each αβ-dimer. After 
tetramerization the receptor autophosphorylates and an extrinsic kinase phosphorylates 
additional tyrosine residues for full activation. The response to insulin stimulation, the cell’s 
sensitivity to insulin, depends on several aspects of cellular signaling, including the number of 
receptors on the surface of each cell and the affinity of ligand binding to the receptor. A 
decrease in a cell’s sensitivity to a particular ligand is called desensitization.[15] Insulin holds 
the ability to desensitize its target cells to its actions through several mechanisms, including at 
receptor level and downstream targets.[16] A brief rise in insulin is stimulatory, while a chronic 
elevated level of insulin (>24h[16]) desensitizes the target cell and leads to generalized insulin 
resistance.[17] Twofold elevations of basal insulin levels are common in patients with insulin 
resistance associated with obesity or type 2 diabetes.[17] 
 
 
1.2.3 Insulin Desensitization and Insulin Resistance 
When the production and distribution of insulin in response to continuously high levels of blood 
sugar, is at an abnormally high rate, the insulin responding cells become desensitized and stops 
responding to insulin. Cells become resistant to insulin, which results in an elevation of blood 
sugar levels (hyperglycemia), and eliminates the ability of cells to take up important nutrients 
like glucose, amino acids and fatty acids. These events subsequently cause the β-cells to 
produce more insulin (hyperinsulinemia), which often is a precursor of insulin resistance. In 
people with insulin resistance, the liver might fail to reduce its production of glucose. In healthy 
individuals the liver reduces the production of glucose from glucagon, in response to the amount 
of circulating insulin. This will also cause the blood glucose to rise. There are several signs and 
symptoms of insulin resistance, including high blood sugar, inability to focus, increased blood 
triglyceride levels, depression and other. The associated risk factors include family history with 
type 2 diabetes, obesity, a tendency to store fat in the abdomen, hypertension, high triglyceride 
levels and others. Insulin resistance is also associated with and often seen as a precursor of 
other metabolic diseases like non-insulin dependent diabetes mellitus (NIDDM), obesity, 
hypertension, dyslipidemia and atherosclerotic cardiovascular disease.[18] 
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1.3 Obesity and Metabolic Inflammation 
1.3.1 The Immune Response 
The immune system protects the human body from the harmful effects of exposure to 
pathogens. The immune system is continuously learning to recognize new pathogens, while the 
pathogens are learning new ways to escape. Pathogens can enter the body in several ways and 
once inside the body, the immune system will recognize it as foreign and start the process of 
elimination; the immune response. An immune response includes the activation and recruitment 
of immune cells. Immune cells, like all blood cells, are derived from the pluripotent 
hematopoietic stem cells (HSCs) in the bone marrow.[19] HSCs are self-renewing and can 
differentiate along two different pathways, producing either myeloid progenitors or lymphoid 
progenitors. Myeloid progenitor cells can differentiate into dendritic cells, monocytes neutrophils, 
macrophages, eosinophils, basophils and erythrocytes. Lymphoid progenitor cells can 
differentiate into natural killer cells, T-cells and B-cells.[19]  
 
The immune system is divided into two categories, depending on the onset of the response. 
The innate immune system is the first response to a pathogen invading an organism. The innate 
immune system is triggered by damage-associated molecular pattern molecules (DAMPs; the 
alarm signals of damaged cells) or by pattern recognition receptors (PRRs), which recognize 
pathogen-associated molecular patterns (PAMPs) associated with microbial pathogens and 
DAMPs.[20] Once the innate immune system is activated, an inflammation will occur. 
Inflammation is characterized by redness, pain, heat and swelling, which reflect the three major 
events of an inflammatory response: vasodilation (an increase in the diameter of blood vessels), 
increase in capillary permeability and an influx of phagocytes from the capillaries into the 
tissue.[19] A long cascade of events involving several chemical mediators initiates the 
inflammatory response. These mediators include chemicals released from damaged cells, 
pathogens and white blood cells, and some are also produced by plasma enzyme systems. 
Examples of pro-inflammatory chemicals include various serum proteins called acute-phase 
proteins (C-reactive protein), eicosanoids (prostaglandins and leukotrienes) and cytokines 
(interferons, interleukins and chemokines), released by infected cells.[21-23]   
 
1.3.2 Obesity 
Obesity is a modern world medical condition, associated with the accumulation of excess body 
fat to the point where it may have adverse effects on a person’s health, life quality and life 
expectancy. Obesity is not only a personal issue, but also a disease with a huge negative 
impact on the nation’s economy. The calculated direct and indirect costs in the United States for 
obesity related medical care in 2005 dollars, was a staggering $190 billion. This number 
accounts for 20.6% of the national health expenditures in the US, indicating that an obese 
person’s medical costs will be $2751 higher than a normal weight person.[24] Being obese 
creates a major predisposition to several diseases, including atherosclerosis, certain cancers, 
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arthritis, type 2 diabetes and specific immune-mediated disorders.[25] The causal factors of 
obesity are many, highly complex and not fully elucidated. Such circumstances include energy 
consumption, activity level, genetics, meal macronutrient composition, and economic, social and 
environmental factors. Over the past several decades, the harmonic equilibrium between the 
aforementioned factors has shifted. A decrease in activity is coupled with an increase in caloric 
intake, fueled by easily accessible, cheap, calorie dense and pre-processed food items.[26] The 
unfortunate outcome of this is a lipid loading of the adipocytes, resulting in an increased mass 
of the human population, leaving 34.9% of the US adult population categorized as obese (Body 
Mass Index >30). [27] 
 
1.3.3 Adipose Tissue 
The most abundant cells in fat, or adipose tissue, are adipocytes. In addition to adipocytes, fat 
contains pre-adipocytes, endothelial cells, fibroblasts, leukocytes and macrophages.[28] The 
number of macrophages in adipose tissue is shown to correlate directly with obesity, and a low-
grade inflammation of the adipose tissue has been characterized as a hallmark of both obesity 
and insulin resistance.[29] In mammals, adipose tissue is found in two forms; white and brown 
adipose tissue. These two types of fat have distinct tasks in the body. While white adipose 
tissue (WAT) is mainly used for the storage of excess energy, brown adipose tissue is 
applicable in the regulation of body temperature, has an elevated number of mitochondria and is 
primarily found in infants.[25]  
 
WAT was previously thought to be an inert tissue, but it is now well established that adipose 
tissue holds important endocrine properties, producing and secreting numerous hormones, 
cytokines and chemokines.[30] The production and presence of the aforementioned pro-
inflammatory molecules, has an unfortunate effect on the metabolic equilibrium in the body. 
Research has shown that pro-inflammatory molecules are associated with a sustained, but low-
grade level of inflammatory changes that seem to arise from the daily challenges of nutritional 
excess.[31] This state of inflammation is called metabolic inflammation.  
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1.3.4 Metabolic Inflammation 
Metabolic inflammation is a term frequently used to describe a low-grade systemic inflammation, 
characterized by the constant production of pro-inflammatory molecules like interleukin-6 (IL-6), 
nuclear transcription factor (NF-κB), leptin, tumor necrosis factor alpha (TNFα) and others.[31] 
Figure 1.3.4.1, shows some of the mediators of NF-κB activation and metabolic inflammation.  
 
 
Figure 1.3.4.1: Mediators of NF-κB activation leading to the production of pro-inflammatory 
cytokine genes and a subsequent inflammation.[32] 
 
 
Metabolic inflammation has several components; among these are endoplasmic reticulum (ER) 
stress, production of reactive oxygen species (ROS), production of pro-inflammatory cytokines 
and more. Activation of several signaling pathways have been associated with metabolic 
inflammation, including signaling through the insulin receptor (IR), which leads to induction of 
ER stress, production of ROS and the subsequent activation of NF-κB.[32, 33] The long-term 
effect of a low-grade systemic inflammation is the development of a cluster of chronic metabolic 
disorders, including obesity, type 2 diabetes and cardiovascular disease.[34] 
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1.3.5 Fatty Acids 
Even though mammals are able to produce certain fatty acids from non-fat precursors like 
glucose and amino acids, this does usually not occur in humans. Because of the high content of 
fat (especially saturated and monounsaturated fatty acids) in the Western Diet, the human body 
does not produce fatty acids from non-fat precursors. However, the only fatty acids mammals 
absolutely cannot produce are the ones that have a double bond between the methyl terminus 
and carbon number nine in oleic acid (OA; 18:1n-9). This means that mammals neither can 
convert oleic acid into linoleic acid (LA; 18:2n-6), nor perform further oxidation of linoleic acid 
into α-linoleic acid (ALA; 18:3n-3).[35] LA and ALA are therefore termed essential fatty acids, 
and are found mainly in plants. Proceeding consummation, LA and ALA can be converted to 
arachidonic acid (AA; 20:4n-6), and eicosapentaenoic acid (EPA; 20:5n-3), docosapentaenoic 
acid (22:5n-3) and docosahexaenoic acid (DHA; 22:6n-3) by the pathways outlined in figure 
1.3.6.1, respectively. EPA and DHA are mainly found in “oily fish” like herring, mackerel, tuna 
and sardines, and also in commercial products called “fish oils”. Studies show[36, 37] that 
human mononuclear immune cells (B- and T-lymphocytes, monocytes) contain 15-25% AA, 6-
10% LA, 1-2% dihomo-γ-LA, and only 2-4% and 0,1-0,8% ALA and EPA/DHA, respectively. By 
increasing the dietary intake of n-3 fatty acids, the proportion of n-3 fatty acids in immune cells 
will increase at the expense of AA levels.[35] In cells with a high content of AA, this will be the 
primary precursor for eicosanoids produced in the cell. Eicosanoids are important in the 
regulation of inflammatory and immune response intensity and duration. Eicosanoids links fatty 
acids to immune function. EPA can inhibit the production of these pro-inflammatory eicosanoids, 
and is therefore a desired component of a healthy diet.[38]  
 
1.3.6 Eicosanoids 
Eicosanoids are derived from omega-3 (n-3) or omega-6 (n-6) fatty acids, where the omega-6 
derived eicosanoids are mainly responsible for the induction of inflammation. The typical 
Western diet contains 20-25-fold more n-6 fatty acids than n-3 fatty acids.[38] The different 
types of eicosanoids include 2-series prostaglandins (PG; ex. PGE2, PGD2 and PGF2), 
thromboxane and 4-series leukotrienes (LT; ex. LTB4), and are produced from several 
precursors by the action of cutaneous cyclooxygenase (COX), terminal prostanoid synthase 
(PGS), lipoxygenase (LOX) and cytochrome P450 (CYP) enzymes. The precursor fatty acids 
from which the eicosanoids are produced include AA and the C-20 polyunsaturated fatty acids 
(PUFA) dihomo-γ-linoleic acid (DGLA; 20:3n-6) and EPA (20:5n-3).[39] Figure 1.3.6.1 shows a 
schematic overview of polyunsaturated fatty acids and the biosynthetic pathways of their 
oxygenated products. 
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Figure 1.3.6.1: Schematic overview of polyunsaturated fatty acids and the biosynthetic 
pathways of their oxygenated products.[39] HODE: Hydroxyoctadecadienoic acid. HETrE: 
Hydroxyeicosatrienoic acid. HETE: Hydroxyeicosatetraenoic acid. EET: 
Epoxyeicosatrienoic acid. DHET: Dihydroxyeicosatrienoic acid. LXA4: Lipoxin A4. PGD2: 
Prostaglandin D2. PGF2a: Prostaglandind F2alpha. PGI2: Prostaglandin I2. TXB2: Series-
2 thromboxane. PGJ2: Prostaglandin J2.  HEPE: Hydroxyeicosapentaenoic acid. RvE: 
Resolvin E-series. RvD: Resolvin D-series. HDHA: Hydroxy-docosahexaenoic acid. 
 
 
PGE2 and LTB4 are the two most studied eicosanoids. LTB4 is a potent enhancer of 
inflammatory responses. LTB4 enhances local blood flow, increases vascular permeability, 
promotes natural killer activity and enhances the production of pro-inflammatory cytokines like 
TNF-α, IL-1β, IL-6, IL-2 and IFN-γ.[40] PGE2 is a biologically active immunoregulator and -
activator[41, 42]. PGE2 promotes immune cell influx to inflamed tissues and inflammatory 
angiogenesis, and is associated with several diseases, including Alzheimer’s disease, RA and 
cancer.[43, 44] EPA can inhibit the synthesis of both PGE2 and LTB4 via competitive inhibition 
of the enzymes that catalyze the metabolism of AA, cyclooxygenase and 5-lipoxygenase, 
respectively.  
 
Phospholipases are responsible for the mobilization of the different fatty acids. Phospholipase 
A2 (PLA2) enzymes catalyze the release of AA from the lipid bilayer. Ca2+ independent PLA2 has 
previously been shown to catalyze the hydrolysis of choline phospholipids (PC), resulting in 
synthesis of monoacyl lysophosphatidylcholine (LPC).[45] The release of free fatty acids is 
mediated by a variety of lipases apart from the phospholipase A2 enzymes, including the 
hormone sensitive lipase (HSL) and triglyceride lipase (TGL). The TGL acts on triglycerides, 
whereas the HSL acts on tri-, di- and monoglycerides (TDMglycerides). [46] TGL has so far only 
	   26	  
been found to be expressed in adipose tissue, while HSL is found to be expressed in various 
tissues, mainly in adipose and steroidogenic tissue.[47]  
 
1.4 cPLA2 
PLA2 is the principle lipolytic enzyme responsible for the release of AA and other PUFAs from 
membrane phospholipids.[48] There are more than 20 different human phospholipases in the 
PLA2 family, located in the cytosol, the cell membrane and extracellularly, secreted from the 
cell. Other than cellular location, the enzymes differ in structure, molecular weight, substrate 
specificity, requirement for Ca2+ and mechanisms of action. Cytosolic PLA2α (cPLA2α) is 
considered to be the main lipolytic enzyme in the release of AA. To be specific, the cPLA2α 
enzyme hydrolyzes an arachidonyl group from the sn-2 position of glycerophospholipids, 
resulting in two products: AA and lysophospholipids. These two products have distinct, 
important tasks in cell signaling. Regulation of cPLA2α activity occurs on several different 
levels, including binding to lipid second messengers, phosphorylation induced kinases, de novo 
gene transcription and an increased intracellular Ca2+ level in response to pro-inflammatory 
stimuli.[49] Several factors have previously been shown to activate cPLA2α and to stimulate 
release of AA, including ATP[50], thrombin[50], IL-1β[51, 52], TNFα[52], PAF[53] and 
lysophosphatidylcholine (lysoPC).[53] 
 
As mentioned in chapter 1.3.4 and showed in figure 1.4.1, AA is one of the fatty acid precursors 
from which the pro-inflammatory eicosanoids are produced.  
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Figure 1.4.1: cPLA2α releases AA from glycerophospholipids. AA is one of the fatty acid 
precursors for the pro-inflammatory eicosanoids. [49, 54] PI3 Kinase: Phosphoinositide 3-
kinase. PKC: Protein kinase C. NIK: NFKB Inducing Kinase. IKK: IKB Kinase. MMP: Matrix 
Metalloproteinase. ICAM: Intercellular Adhesion Molecule. iNOS: Nitric Oxide Synthase. 
 
 
The activity of cPLA2α has been found to be upregulated in multiple inflammatory diseases like 
Psoriasis[55], Parkinson’s Disease[56], Alzheimer’s[57] and several types of cancers[58], 
including colorectal, small bowel and lung. Another inflammatory disease where cPLA2α has 
been shown to play a role is Rheumatoid Arthritis (RA), an inflammatory disease of the joint. RA 
is an autoimmune and systemic inflammatory disease with a poorly understood 
etiopathogenesis.  
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1.5 Autoimmune Diseases 
The immune system protects the human body from infections and diseases by recognizing 
foreign structures entering the body. Once recognized, the cells of the immune system continue 
to target and eliminate invading microbes, infected cells and tumors while ignoring healthy 
tissue. In some cases, for reasons still not understood, the immune system targets antigens of 
the host healthy tissue (self-antigens). This event is called autoimmunity and it is characterized 
by an abnormal immune reactivity in association with autoreactive B and T cell responses. 
Multiple factors are thought to contribute to the development of autoimmunity, including genetic, 
immunological, hormonal and environmental factors.[59] Why the immune system suddenly 
recognizes self-antigens as foreign is not fully elucidated. Some autoimmune responses are 
induced by pathogenic infection, where the pathogen proteins resemble proteins of the host, 
structurally. Predisposition to autoimmunity occurs when there are specific genetic variations in 
the allele(s) that controls antigen presentation by antigen-presenting cells for T-cell 
recognition.[60] In RA, circulating autoantibodies have been detected. A negative autoantibody 
test does not rule out RA, but a positive test does not occur in healthy patients. There are more 
than 80 types of autoimmune diseases, which can be divided into organ-specific illnesses 
(thyroid disease, type 1 diabetes etc) or systemic illnesses (RA, systemic lupus erythematosus 
etc).[61]  
 
1.6 Rheumatoid Arthritis 
Rheumatoid Arthritis (RA) is the third most common type of arthritis in the US, affecting 
approximately 1.3 million people in the US and about 1% of the world population.[62] RA is a 
systemic inflammatory and autoimmune disease of the synovial membrane that lines the non-
weight bearing surface of joints. In RA, the quiescent and relatively acellular, healthy synovium 
becomes a hyperplastic, invasive tissue teeming with immunocompetent cells.[63] The chronic 
synovitis causes pain, swelling and loss of joint function due to degradation of cartilage and 
bone erosion.[49] In healthy joints the synovial membrane produces lubricating and nourishing 
synovial fluid and comprises two cell types; macrophage-like (Type A) and fibroblast-like (Type 
B) synoviocytes (FLSs).[64] In diseased joints, T cells and B cells will invade the synovial 
membrane resulting in a hyperplastic synovial tissue, which becomes invasive, destroying the 
articular cartilage and underlying bone (Fig. 1.6.1). In RA, the FLS will contribute to the   
elevation of produced pro-inflammatory cytokines (especially IL-1β) and molecule mediators of 
inflammation, as well as matrix metalloproteinases (MMPs), which are responsible for joint 
erosion.[65] It has also been stated that targeting the FLS might improve clinical outcomes in 
RA without suppressing systemic immunity.[63] 
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Figure 1.6.1: In a healthy joint (left side) a thin synovial membrane is seen, enclosing the 
synovial fluid. In RA (right side) the synovial membrane is hyperplastic and infiltrated by 
chronic inflammatory cells.[64] 
 
 
A very important equilibrium in joints is that between bone formation and bone resorption. 
These repeated cycles of construction and destruction are controlled by osteoblasts and 
osteoclasts, respectively, and are important in the maintenance of bone mass.[66] An 
imbalance in bone remodeling, such as an excessive osteoclast-induced bone resorption can 
cause several diseases including osteoporosis, RA and cancer metastasis to the bone.[67] The 
regulation of differentiation and activation of osteoclasts is affected by several molecules, such 
as receptor activator of NF-κB ligand (RANKL), which activates RANK receptor. Once RANK is 
activated on osteoclast progenitor cells, the subsequent activation of TNF receptor-associated 
factors and several signaling cascades, including NF-κB, mitogen-activated protein kinase 
(MAPK), activating protein 1 (AP-1) and nuclear factor of activated T cells (NFATc1), leads to 
the formation of bone-resorbing osteoclasts.[67] 
 
As mentioned in the previous chapter, there are multiple factors involved in the onset of an 
autoimmune disease like RA, even though the aetiology and pathogenesis of RA remains 
unsolved. In some patients, circulating autoantibodies have been detected. Such autoantibodies 
include rheumatoid factor and anti-cyclic citrullinated peptides (CCP), against the Fc region of 
other antibodies and against citrullinated epitopes on post-translationally modified proteins, 
respectively.[68] There is strong genetic linkage to chromosome 6, more specific the class II 
major histocompatibility complex (MHC) region.[69] There is also evidence of an association 
with the non-MHC gene PTPN22, which is a phosphatase that regulates T-cell activation. Even 
though there is evidence that genetic factors are related to an increased risk of RA, RA is a 
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multifactorial disease resulting from the interaction of both genetic and environmental factors. 
The sole environmental factor associated with RA is cigarette smoking.[70] Inflammation is 
mediated by pro-inflammatory cytokines (including TNFα, IL-1β, IL-6, IL-15 and IL-17) and 
tissue destructive enzymes (MMPs) in RA. T cells, macrophages, type B synoviocytes and 
bone-destructive osteoclasts produce these molecules, and all of these cells are involved in the 
pathology of RA.  
1.7 An In Vitro Model for Synovitis 
The SW982 synoviocyte cell line is a model for synovitis, and has previously been used to study 
RA.[65, 71-73] These are human fibroblast-like synoviocytes (FLSs), collected from a biphasic 
synovial sarcoma found in a 25-year-old Caucasian female. Leibovitz initiated the cell line in 
1974 at the Scott and White Clinic, Temple, Texas.[74-76] According to immunohistochemical 
studies performed by McNearney et al, the SW982 cell line has characteristics consistent with 
the phenotype of type B synovial cell fibroblasts. Type B synoviocytes is the most abundant cell 
type in the RA synovium, together with synovial macrophages (type A synoviocytes) and 
infiltrating T lymphocytes.[77] SW982 cells can be purchased from the American Type Culture 
Collection (AATC), a private, non-profit biological resource center (BRC) and research 
organization.[78] 
 
Animal cell culturing became a common laboratory technique in the mid-1900s, and today the 
technique also includes cultures of plants, fungi, insects and microbes, including viruses, 
bacteria and protists. When culturing animal cells, there are two different main types of cells; 
primary cells and cell lines. Primary cells are cultured directly from a subject (for example a skin 
sample) and have a limited lifespan. Immortalized or established cell lines, like the SW982 cell 
line, evades normal cellular senescence and can be studied for a longer period of time in vitro. 
There are many benefits of using primary FLSs from patients in the study of RA, but also 
several drawbacks, including difficulties to collect and establish. SW982 has been shown to 
express pro-inflammatory cytokines IL-6, IL-8 [79], IL-1β and Transforming growth factor (TGF)-
β, and also matrix metalloproteinases (MMPs) 1, 2, 3 and 13[65], intracellular adhesion 
molecule-1 (ICAM-1) and COX-2. mRNA expression of these genes have been shown to be 
upregulated by stimulation with IL-1β.[65] Prof. Johansen and group showed in 2013 that TNF 
increases mRNA levels of MMP3 and IL-8.[49] Prof. Johansen and group also showed in 2014 
that SW982 cells express a wide repertoire of PLA2 enzymes. PLA2 subgroups GIIA, GIVA, 
GVC, GV, GVIA, GVIB, GVIC, GVID, GVIF, GVIIA, GX and GXIIA were found to be expressed 
in cultured SW982s.[80] They also detected the expression of TLRs1-7 in SW982 synoviocytes. 
TLR2 expression was found to be upregulated by TNF, and TLR2 ligands Pam3CSK4 and FSL-1 
were found to induce the activation of cPLA2, which in turn regulates the expression and 
production of IL-6, IL-8 and COX2/PGE2.[80]    
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1.8 Objectives 
A pilot study published by Prof. Johansen and her group in 2013, studied the gene expression 
in blood in a group of obese men who had shifted from their normal diet to a strictly defined diet, 
with a fixed number of meals, serving sizes and macronutrient composition (decrease in dietary 
carbohydrates and an increase in dietary proteins). Already at day 1 of the intervention, there 
was a significant change (increase or decrease) in gene expression, which remained at that 
new level throughout the diet period of 28 days.[81] Genes that were downregulated in this 
period included genes associated with processes relying on B-lymphocyte activation. Genes 
involved in metabolic processes like protein modification and biosynthesis were found to be 
upregulated during the intervention pilot study.[81] Meaning that the macronutrient composition 
of the diet plays a role for the low-grade systemic inflammation. 
 
In a 2010 quantitative patient questionnaire monitoring in standard clinical care of patients with 
rheumatoid arthritis (QUEST-RA) study, Dr. Jawaheer et al. analyzed a total of 5161 RA 
patients (4082 women and 1079 men), collecting complete data concerning their age, gender, 
BMI, disease duration and Disease Activity Scores based on a 28-joint count (DAS28 scores). 
The mean DAS28 scores among patients in different BMI categories increased with increasing 
BMI in most countries, as well as in the combined dataset for all countries.[82]  
 
These findings underpin other similar studies[83-85], and may suggest that the caloric intake 
and the macronutrient composition of our diet influences the low-grade systemic inflammation in 
the body, and potentially has an effect on inflammatory diseases like RA. If a person with RA 
consumes a typical Western diet, relatively rich in dietary carbohydrates and scarce in dietary 
proteins, in amounts exceeding the daily caloric need, would this affect the disease activity? 
Would the excessive secretion of insulin affect the hyperplastic synovium, causing it to hyper 
proliferate? 
 
A diet rich in carbohydrates will stimulate secretion of insulin. Are SW982s amenable to insulin 
stimulation? If dietary changes like the ones stipulated above, will downregulate genes 
associated with immunity, will excess amounts of insulin stimulate an upregulation of genes 
associated with immunity in fibroblast-like synoviocytes? Will insulin stimulation lead to hyper 
proliferation of fibroblast-like synoviocytes? Can the findings in the FLS’ be the foundation of 
new dietary advices for patients suffering from RA? 
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2. Methods and Materials 
2.1 Cell Culture 
Fibroblast-Like Synoviocytes (SW982s) were purchased from the American Type Culture 
Collection (ATCC). Cell culturing medium (Dulbecco’s modified eagle’s medium; DMEM), L-
glutamine, dimethyl sulfoxide (DMSO), Gentamicin solution and fatty acid free bovine serum 
(FBS) was purchased from Gibco. Cells were cultured in 75 cm2 and 175 cm2 cell culture flasks 
purchased form Sarstedt. Cells were cultured in Dulbecco’s modified eagles medium (DMEM) 
with 10% Fetal Bovine Serum (FBS), 3% Glutamine and 1000 µL gentamicin added. This 
solution will be referred to as “DMEM10%” for the remaining of the thesis. Cells were 
subcultured twice every week and discarded at passage ~50 or earlier if there were signs of 
change of character. Signs of change of character could be morphological changes (smaller 
size, rounder edges) and a sudden change in the rate of mitosis. When the cells were used for 
stimulation experiments, they were plated in DMEM10% and left to settle for 24 hours (unless 
otherwise stated). The cells were then starved with starvation media, serum-free DMEM + 3% 
glutamine, from now on referred to as SF-DMEM.  Starvation period was set to 24 hours (unless 
otherwise stated).  
 
2.2 Growth Curve 
A growth curve shows a model of the evolution of a cell population over time. Cells in culture 
grow either attached to a surface (anchorage dependent) or in suspension (anchorage 
independent). The SW982s grow attached to the surface in a monolayer, and follows a 
characteristic growth pattern of four phases: lag, log, stationary and decline phase. The lag 
phase is the first phase after seeding of the culture vessel. During this phase the cells grow 
slowly as they are still recovering from the stress of subculturing. As the cells settle down, they 
start dividing at a higher rate and enter the next phase: the log phase. During the log phase the 
cells experience an exponential growth until the entire growth surface is covered with cells. 
During the stationary phase, cell proliferation slows and stops. The cells enter a decline phase 
where cell viability and number decreases if the culture medium is not replaced and the cell are 
not subcultured.[86]   
 
Confluency is a term used to describe the percentage of growth surface covered with cells. At 
100% confluency, there is no available growth surface between the cells and the cells are 
confluent. Prior to 100% confluency, the cells are subconfluent and there is still available growth 
surface between the cells. At this stage they are still in the log phase. After the cells have 
become confluent, they enter post-confluency and are in the stationary phase. In this phase, the 
cells stop concentrating on mitosis and focus on the activities that are characteristic for 
fibroblast-like synoviocytes.  
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At day 0, cells (generation #41) were plated in 6 mL DMEM10% (DMEM containing 10% FBS, 
1mL gentamicin and 3% glutamine) in T25 culture flasks at 25 000, 100 000, 250 000, 500 000 
and 800 000 cells per flask. Cells were cultured for 8 days in a total of 32 T25 flasks (8 flasks 
per initial cell seeding). One flask of each cell seeding was studied and harvested each day 
starting at day 1, to determine confluency and cell number (using a Bürcher chamber). Each 
flask was counted one time with 3 technical replicates, cells were returned to their flask for 
determination of confluency each of the remaining days of the experiment. Any confluency 
below 40% was noted as “K<40%”. A slope for the entire growth period and for the log-phase 
alone was determined using Excel. 
 
A second growth curve experiment was conducted using the same culture flasks and otherwise 
identical experimental setup as for growth curve 1. This time, cells were plated at 25 000, 100 
000, 250 000 and 500 000 in the used flasks, and an additional 8 new T25 flasks were plated 
with 800 000 cells per flask at day 0. One flask from each cell seeding was counted each day 
with 3 technical replicates, and the cells were subsequently returned to their flask for 
determination of confluency for the remaining of the 8 days. 
 
2.3 Arachidonic Acid Release Assay 
A release assay with radioactively labeled molecules has the purpose of measuring the ability of 
a given selection of cells to either take up or release the molecule in question. In the case of the 
fatty acid Release Assay performed on the SW982s, [3H]-Arachidonic Acid and [14C]-Oleic Acid 
is incorporated into the plasma membrane of the cells. Subsequently, the release of the 
respective fatty acids is measured, in response to a given stimuli. Release assays where the 
stimulant induces increased release of AA and not OA, may indicate an activation of the 
arachidonyl-specific cPLA2α enzyme.[52] 
 
Release assay was performed on cells in subconfluent, confluent and post-confluent states 
plated in 48-well plates at 50 000 cells per well in 0.5 mL DMEM10%. The cells (generation #38-
42) are left to grow until they reach the desired degree of confluency: 12, 24 and 72 hours 
respectively. After the growth period the cells were starved in 250 µL SF-DMEM for 24 hours. 
During starvation, 3.3 µL/mL [3H]AA and 0.67 µL/mL [14C]OA was added to the starvation media 
to label the cells. After starvation and labeling, the medium was removed and the cells were 
washed twice with 1 mL prewarmed SF-DMEM, the first wash containing 0.2% fatty acid free 
bovine serum albumin (fBSA). After washing, 160 µL stimulation medium was added to the 
wells and left on for 4, 8, 16, 24 or 48 hours. After stimulation the supernatant was transferred to 
individual 1.50 mL eppendorf tubes. The cells were lysed with 200 µL, 1M sodium hydroxide 
(NaOH) for 24 hours at 22°C. The supernatant was centrifuged for 5 min at 13200 rpm and 
24°C. After centrifugation, the 160 µL of supernatant was transferred to 2 mL eppendorf tubes 
containing 1 mL scintillation fluid. Then the lysed cells were transferred to new 2 mL eppendorf 
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tubes containing 1 mL scintillation fluid. The samples were analyzed in a Wallac 1409 liquid 
scintillation counter. 
 
Cells were stimulated with insulin suspended in SF-DMEM, at different concentrations for 4, 8, 
16, 24 and 48 hours (for subconfluent cells), and 24 hours for confluent and post-confluent cells. 
All cells were treated with 1 µM insulin for the indicated hours. Cells stimulated for 48 hours 
were treated with 3 different concentrations of insulin; 0.3, 1 and 3 µM. SF-DMEM with or 
without IL-1β (10 µg/mL) were included as positive and negative controls, respectively.  
 
2.4 MTT viability assay 
The MTT viability assay is a semi-automated colorometric assay, invented by Mosmann in 
1983.[87] MTT is an abbreviation for 3,4,5 dimethylthiazol-2,5 diphenyl tetrazolium, and the 
assay is based on the ability of mitochondrial dehydrogenase enzymes of living cells to convert 
MTT to a purple formazan precipitate. These mitochondrial succinate dehydrogenases may 
reflect the number of viable cells present, but may also reflect the rate of cellular respiration. 
Therefore, the results should be validated by additional techniques as well. The resulting 
crystals are subsequently dissolved using dimethyl sulfoxide (DMSO) and the optical density of 
each well is measured using a multiwall plate reader.[87] This assay is simple, rapid and 
affordable, but will also render the cells non-viable meaning that repeat or complementary 
assays cannot be carried out on the same plate of cells. 
 
For the “Timeline” assay, cells were plated in 96-well plates in DMEM10%. Cells were plated at 
2500, 5000, 10 000, 15 000 and 25 000 cells per well, and starved after 24 hours, for 24 hours 
in SF-DMEM. After starvation cells were stimulated with 100 µL, 1 µM insulin. Some wells got 
SF-DMEM or DMEM10% as negative and positive controls, respectively. Cells were stimulated 
for 24, 36 or 48 hours. After stimulation the stimulation medium was removed and 100 µL MTT 
was added and left on for 2 hours. MTT was removed and 100 µL DMSO was added. The 
plates were analyzed in a plate reader at optical density of 550 and 595 nm.  
 
For the “Dose Response” assay, cells were plated in 100 µL DMEM10% at 2500 and cells per 
well in a 96-well plate. Cells were starved with SF-DMEM after 24 hours, for 24 hours. Cells 
were stimulated with insulin (0.3-3 µM), SF-DMEM or DMEM10%, for 48 hours. After stimulation 
the protocol for “Timeline” assay was followed.  
 
2.5 MTT Data Analysis Using Excel 
All MTT data were analyzed using Microsoft Excel 2010, including fold changes, standard 
deviations and significance. The 2-tailed, paired student’s T-test was used for calculating 
statistical significance between means of biological replicates. 
 
	   35	  
2.6 Flow Cytometry as a Validation for MTT 
Flow cytometry is a rapid analysis based on optical and fluorescent measurements, yielding 
qualitative and quantitative information about cells. Flow cytometry can be used to analyze 
several different samples, including blood specimens, bone marrow, serous cavity fluids, 
cerebrospinal fluid, urine, solid tissue and cultured cells.[88] Flow cytometry can be used to 
analyze several different aspects of a cell, including cell size, cytoplasmic complexity, DNA/RNA 
content, and also membrane-bound and intracellular proteins. In order to measure the 
aforementioned characteristics, the specimen is pretreated with specific dyes that can bind to 
cellular components like DNA or RNA, such as propidium iodide, phycoerythrin, fluorescin or 
others.[88] In flow cytometry single cells from a sample pass through an illumination zone at 
~300 cells per second (higher rates are possible). Electronically gated detectors measures the 
extent of light scattered, which results in the display of histograms of the number of cells 
possessing a certain quantitative property versus the channel number.[89] 
 
Cells were plated in DMEM10% at 200 000 cells per well in a 6-well plate. Cells were starved in 
SF-DMEM after 24 hours, for 24 hours. After starvation the subconfluent cells were treated with 
1.0 µM insulin for 48 hours. Cells were subsequently washed with PBS twice and treated with 
0.5 mL trypsin for 2 min. 1.0 mL DMEM10% was added and the cells were transferred to a 15 
mL centrifuge tube. Cells were spun at 700 rpm for 5 min, and the supernatant was discarded. 
Cells were carefully resuspended in 2.0 mL methanol (-20°C). Cells were subsequently spun at 
700 rpm for 5 min, and resuspended in 1 mL RNase (200 µg/mL). Cells were spun again at 700 
rpm for 5 min, and resuspended in propidium iodide (40 µg/mL). Samples were analyzed using 
a Becton Dickinson LSR at the institute of physics at NTNU. 
 
2.7 RNA Isolation 
Ribo Nucleic Acid (RNA) is a highly regulated and unstable, single stranded molecule with 
numerous biological functions. The messenger RNA (mRNA) is the cells’ first step towards 
protein expression, and capturing the levels of mRNA at a specific time will reveal which genes 
are transcribed and how they are transcribed in relation to each other. RNA is extremely 
sensitive to degradation by RNases and therefore any handling of RNA should be quick, kept on 
ice, clean and performed the same way each time. 
 
All RNA isolations were performed according to Qiagen’s protocol for the RNeasy Mini Kit. Cells 
were lysed in 700 µL RLT lysis buffer, containing 1% Beta-Mercaptoethanol. The RNeasy Mini 
Kit is based on the use of spin columns to bind, wash and eluate total RNA from cells and 
tissues. Eluated RNA was kept on ice at all times and stored at -80 °C.  
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2.8 Nano Drop for Quality and Yield Assessment of RNA 
The spectrophotometer NanoDrop ND-1000 uses UV light to make quantitative and qualitative 
assessments of nucleic acids and proteins. The NanoDrop measures absorbance between 200 
and 350 nm. The absorbance at 260 nm is used to determine the concentration of RNA. Two 
ratios are important for assessing contamination of the RNA sample: 260/280 and 260/230. 
Both of these ratios should be at 2.0, and no less was accepted in this study. Ratios <2.0 
indicate protein (or other components that absorb strongly at 280 nm) and carbohydrate 
contaminations, respectively. Through wavelength in a sample should be ~230 nm, and the 
peak at 260 nm. RNA concentrations >150 ng/µL was accepted for use in further analysis. 
 
2.9 cDNA Synthesis 
Complimentary DNA (cDNA) is a double stranded DNA molecule made from a RNA template, 
by reverse transcriptase and DNA polymerase. The cDNA molecule is more stable than RNA 
and therefore easier to analyze. Because cDNA is chemically identical to genomic DNA (gDNA), 
it is important to remove all potential gDNA contamination in the RNA sample before analyzing 
it.  
 
cDNA synthesis was performed as stated in Qiagen’s protocol, using reagents in Qiagen’s 
QuantiTect Reverse Transcription Kit. For each cDNA sample, 1000 ng of RNA was used. This 
kit involves a step for gDNA removal, synthesis of cDNA and an end-reaction. Random primers 
are used in the conversion of mRNA to cDNA, meaning that cDNA is produced from all mRNA 
molecules in the sample. The whole process takes approximately 30 minutes. 
 
RNA samples were thawed on ice (stored at -20°C), spun down briefly and RNA concentrations 
were measured with NanoDrop. 1000 ng of RNA was used in each cDNA reaction. 2 µL of 
gDNA wipeout buffer was added to a total of 12 µL of RNase-free H2O and template RNA 
(varying amounts of the two depending of RNA concentration in sample), and incubated at 42°C 
for 2 minutes. After the incubation, 1 µL Quantiscript RT, 4 µL Quantiscript RT Buffer 5x and 1 
µL RT Primer Mix was added to the samples, adding up to a totalt reaction volume of 20 µL.[90] 
This was incubated at 42°C for 15 minutes, and finally at 95°C for 2 minutes to stop the 
reaction. cDNA was stored at -20°C.   
 
2.10 RT-qPCR 
Since the invention of conventional polymerase chain reaction (PCR) 31 years ago, the method 
has been adapted several times for novel molecular biology approaches and is now able to 
detect minute amounts of nucleic acids.[91] The reverse-transcription real-time quantitative 
polymerase chain reaction (RT-qPCR) is a popular method for gene expression analysis, 
supporting protein expression data from proteomics-based assays, supporting phenotypic 
observations, validating micro-array experiments, monitoring biomarkers and more.[92, 93] 
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Several methods of qPCR and RT-PCR have been developed and several detection systems 
are used, including agarose gels, fluorescent labeling of PCR products with subsequent 
detection of laser-induced fluorescence using capillary electrophoresis or acrylamide gels, plate 
capture and sandwich probe hybridization.[94] The RT-qPCR process is based on a series of 
temperature changes, which are repeated 25-40 times. Each temperature defines the optimal 
temperature for DNA denaturation (95°C), binding of primers (55°C) and extension of single-
stranded DNA molecules (72°C). The main difference between the conventional PCR and the 
RT-qPCR is the continuous quantification of PCR products in the latter. The RT-qPCR system 
detects the products at the end of each cycle by using a non-specific fluorescent dye, SYBR 
Green, which binds to double-stranded DNA. An increase in DNA product will cause increased 
fluorescence intensity, but the quantification of DNA is relative to an internal reference gene. At 
the end of an RT-qPCR process, the system allows you to analyze several aspects of the 
procedure, like the DNA melting temperature (Tm) of specific fragments, primer efficiency, the 
quantification cycle values (Cq) and the fluorescence for each sample plotted against the 
number of cycles on a logarithmic scale.[91]   
 
cDNA samples were thawed and kept on ice, and prepared for analysis using the QuantiTect 
SYBR Green RT-PCR Kit from Qiagen. Each well was loaded with 5.0 µL cDNA (diluted 1:10), 
10.0 µL SYBR Green I, 1.2 µL primer (forward + reverse) and 3.8 µL PCR grade water. Primer 
mixes with equal amount of forward and reverse primers, were prepared for target genes (INSR, 
IGF1R, c-Myc, c-Fos and IL-6) and for reference genes (18S ribosomal rRNA, hypoxanthine-
guanine phosphoribosyltransferase (HPRT) and β2 microglobulin (B2M)). The plate was sealed 
and centrifuged before use. RT-qPCR was carried out on a Light Cycler 480 machine in 96-well 
plates. The Light Cycler has a program with cycling conditions obtained from the RT-qPCR 
primer assay handbook and included: denaturation for activation of DNA polymerase for 3 
minutes at 95 °C (optimized by the PLA2 group), 40 cycles of 15 seconds at 95°C for 
denaturation of double stranded cDNA, 40 seconds of 55°C for annealing of primer and single 
stranded DNA, 30 seconds of 72°C for extension of new DNA strand and quantification of 
fluorescence. 
 
 
 
 
 
 
 
 
 
 
 
	   38	  
Table 2.10.1: Primers used in RT-qPCR experiments. 
 
 
The PLA2 research group designed some of the primers used in the RT qPCR experiments in 
this master’s thesis, and some were ordered directly from Sigma Aldrich. 
 
 
The RT qPCR data were analyzed using LinReg and Microsoft Excel 2011. 
 
2.11 RT-qPCR Data Analysis Using LinReg  
LinReg is a program, which makes it easier to analyze the quantitative RT-qPCR data retrieved 
from the Light Cycler 480 after completion of the cycling process. LinReg determines baseline 
fluorescence and does a baseline subtraction, subsequently calculating the respective threshold 
cycle (Ct)-values and PCR efficiencies per sample, and also an average PCR efficiency per 
amplicon group. Data calculations from LinReg were further analyzed in Microsoft Excel.  
 
2.12 RT-qPCR Statistics 
All RT-qPCR data were analyzed in Microsoft Excel after baseline and Ct calculations in 
LinReg. The Ct is determined from a log-linear plot of the PCR signal versus the cycle 
number.[95] All cDNA samples were analyzed by RT-qPCR in duplicates, to control technical 
variability. Only technical duplicates varying with less than 0.5 cycles were included in further 
analysis. Reference genes, or housekeeping genes, were also analyzed with RT-qPCR, as an 
internal control gene to normalize the PCRs for the amount of RNA added to the reverse 
transcription reactions. Expression levels of samples were calculated as relative quantification, 
compared to untreated controls. The most common method for calculating the relative 
Entrez ID Gene Forward Primer Reverse Primer 
3643 INSR CTGGATTCCGTGGAGGATAA  GCAGCCGTGTGACTTACAGA 
3480 IGF1R GCCGAAGGTCTGTGAGGAAGAA  GGTACCGGTGCCAGGTTATGA 
100820712 c-Fos GTGGGAATGAAGTTGGCACT  CCGGGGATAGCCTCTCTTAC 
4609 c-Myc AAAGGCCCCCAAGGTAGTTA  TTTCCGCAACAAGTCCTCTT 
3569 IL6 TGTGTGAAAGCAGCAAAGAG  GCAAGTCTCCTCATTGAATCC 
3251 HPRT ATGGTCAAGGTCGCAAGC  ATTCATTATAGTCAAGGGCATATCC 
567 B2M GAATTCACCCCCACTGAAAA  AGCAAGCAAGCAGAATTTGG 
100008588 18S GTAACCCGTTGAACCCCATT  CCATCCAATCGGTAGTAGCG 
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expression is with the 2-ΔΔCt equation, where one of several assumptions is that the amplification 
efficiencies of target and reference is approximately equal.[95] An other way to calculate the 
relative quantification of a target gene in comparison to a reference gene, is to determine the 
relative expression ratio (R) based on the specific primer efficiency and the Ct deviation of a 
sample versus control. This is then expressed in comparison to a reference gene[96]: 
 
  Ratio (R) = 
 
 
Mean Ct, variation of Ct and ΔCt was calculated in Microsoft Excel. Statistical significance was 
calculated based on the relative expression values of target genes and expression values of 
control genes in comparison to the mean value of the respective control genes, as described by 
Livak et al.[95] Statistical significance was investigated using a two-sample t-test, the Student’s 
T-test, where the sample sizes and variance are equal. The degrees of freedom for this test is 
2n-2, n is the sample size. The null hypothesis is that the means of two independent samples 
are equal. The chosen threshold for the calculated p-value is 0.05, and the null hypothesis is 
rejected whenever the p-value is < 0.05.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(ETarget) ΔCtTarget(control-sample)	  
(ERef) ΔCtRef(control-sample)	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3. Results 
3.1 Reuse of Culture Flasks Reduce Lag Phase in SW982 Cells 
A growth curve for cells in culture commonly has three phases that are observed in the 
laboratory: the lag-phase, the log-phase and the stationary phase. During the lag-phase the 
increase in cell number will be none or small. During this phase the cells spend time and energy 
on metabolic activities like enzyme synthesis, cell-cell communication and attaching to the 
surface of the culture flask. Once the cells have established communication and produced 
proteins and enzymes for proliferation they transit into the log phase. During the log-phase the 
cells experience an exponential growth until there is no available surface left to grow on, or they 
are starved for serum. The SW982s are cells that grow in a monolayer and will stop proliferating 
once they occupy 100% of the growth surface. When the cells reach this stage they transition 
into the last phase: the stationary phase. During this phase the cells stop proliferation and 
differentiate, fulfilling specific functions. Do cells spend less time in the lag-phase when they are 
plated in used flasks?  
 
Cells were seeded at 25 000, 100 000, 250 000, 500 000 and 800 000 cells per culturing flask in 
DMEM10%, and observed for the following 8 days. 8 culturing flasks were used per cell 
seeding, and for each day of the experiment one flask was counted using a Bürcher chamber. 
Confluency was determined before counting in every flask each day of the experiment. Cells 
with a low initial cell number spent longer time in the lag-phase, than the cells with a higher 
initial cell number. Cells plated at 25 000 cells per flask entered the log-phase at day 5, and 
stayed in this phase for the remaining 3 days of the experiment. Cells plated at 100 000 cells 
per flask entered the log-phase at day 3 of the experiment. Cell number reached a plateau at 
day 7 of the experiment, as they transitioned into the stationary phase. Cells plated at 250 000 
cells per flask entered the log phase at day 2, and subsequently transitioned into the stationary 
phase at day 5. Cells plated at 500 000 cells per flask entered the log-phase at day 1. These 
cells stayed in the log-phase until day 5, when they entered the stationary phase. From day 7 to 
day 8 a slight decrease in cell number was observed, indicating that the cells entered the 
decline phase. Cells plated at 800 000 cells per flask started off in the log-phase, skipping the 
lag-phase. These cells had an exponential growth until day 4, where the number of cells started 
to decline slightly until the end of the experiment (figure 3.1.1). 
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Figure 3.1.1: Growth curve for SW982s plated in T25 culture flasks at different cell number. 
Numbers indicate average number of cells per flask per day of the 8-day-experiment. Error 
bars indicate standard deviation after three technical replicates.  
 
 
The slope of a linear model of the log phase of the growth curve was calculated for each initial 
cell seeding. Slopes for the log phase of the growth period increased with increasing cell 
seeding, but not proportionally with the number of cells. The slope for cells seeded at 800 000 
cells is only ~2x the slope of cells seeded at 25 000 cells, even though there are ~32x cells. 
Slopes calculated for cells seeded at 25 000, 100 000, 250 000, 500 000 and 800 000, were 
based on days 4-8, 3-7, 2-6, 1-5 and 0-4, respectively. All slopes are presented as x104 and 
listed along with definitions of log phases in table 3.1.1. 
 
Table 3.1.1: Slopes were calculated for the log phase of the growth curve experiment, for each initial cell 
seeding. The table lists the slope and each initial cell seeding, and the days defining the log phase are 
listed in the latter column. 
Initial Cell Seeding Slope Of Log Phase 
(x104) 
Days Defining Log 
Phase 
25 000 403 5-8 
100 000 649 3-7 
250 000 740 2-5 
500 000 815 1-5 
800 000 921 0-4 
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The confluency of the cells is a number explaining how many percent of the growth surface is 
covered with cells. Cell confluency below 40% is a very sparsely packed group of cells, where 
many of the cells may not have direct contact with other cells. Cell confluency at 100% is a very 
densely packed group of cells, where there is no growth surface available. 
 
Cells plated at 25 000 cells per flask reached 40% confluency at day 4. These flasks showed a 
slight increase in confluency over the next couple of days, and had reached a confluency of 
85% at day 8. Cells plated at 100 000 cells per flask reached 40% confluency at day 3, showing 
a slight increase over the next day, and subsequently reaching 100% confluency at day 8. Cells 
plated at 250 000 cells per flask reached 40% confluency at day 2 and had by day 6 reached 
100% confluency, which it maintained throughout the remainder of the experiment. Both cells 
plated at 500 000 and 800 000 cells per T25 flask were at 40% confluency already at day 1, 
reaching a confluency of 100% at day 3. The cells remained at 100% confluency throughout the 
experiment (figure 3.1.2).  
 
Figure 3.1.2: Progression of cell confluency per day of the 8-day growth curve experiment, 
one curve for each cell number plated. Shows the confluency of the T25 culture flasks 
behind figure 3.1.1, for the 8 days of the growth curve experiment. Cell confluences below 
40% are referred to as “<40%”. 
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The T25 culture flasks applied in the first growth curve experiment were washed and reused to 
repeat the experiment. Hence, the new cells were introduced to an environment in which cells 
had already established cell-extracellular matrix (ECM) communication and proteins used to 
attach cells to the growth surface. The cells were plated in DMEM10% at four different cell 
numbers: 25 000, 100 000, 250 000 and 500 000. 8 flasks were used per cell number and for 
each day of the experiment, one flask was used to determine confluency and subsequently 
counted using a Bürcher chamber. 
 
In the second growth-curve experiment no lag-phase was observed in used culture flasks. Cells 
plated at 25 000 reached the stationary phase at day 4, 2 days quicker than in the first 
experiment. Cells plated at 100 000 and 250 000 cells remained in the log-phase until day 3, 
and had a slight increase in cell number throughout the growth experiment. Compared to the 
first experiment, cells plated at 100 000 and 250 000 cells reached the stationary phase 4 and 2 
days earlier in the second experiment, respectively. Cells plated at 500 000 cells had a steep 
linear growth curve the two first days, and had a slight increase in cell number until day 4, when 
it reached the stationary phase. In the first experiment, the growth was exponential until day 4 
(figure 3.1.3).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1.3: Growth curve for SW982s plated in T25 culture flasks at different cell 
number. Numbers indicate average number of cells per flask, per day of the 8-day-
experiment. One biological replicate. Error bars indicate standard deviation after three 
technical replicates (3 counts). 
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Slopes were also determined for growth curve 2, as for growth curve 1. Slopes for the log-phase 
were calculated based on a linear model of the growth curve. For cells seeded at 25 000 cells 
per flask the slope of the log phase increased by 80%, in the second experiment, which was the 
biggest increase in slope.  Cells seeded at 100 000 cells, had a much shorter log phase in the 
second experiment, and the slope of the log phase by 42% in the second experiment. Cells 
seeded at 250 000 cells produced a slope in the second experiment that was 31% higher than 
in the first experiment. Cells seeded at 500 000 cells exhibited a slope that was 41% higher in 
the second experiment than in the first experiment (table 3.1.2). 
 
 
Table 3.1.2: Slopes were calculated for growth curve 2 based on a linear regression of the log 
phase of their growth period.  Table presents initial cell seeding, slope for log phase and the 
days of the growth experiment defining the log phase. 
 
 
 
 
 
 
 
 
 
As for growth curve 1, confluency was evaluated throughout the experiment of growth curve 2. 
Figure 3.1.4 shows the progression of confluency for the four cell numbers plated in the used 
T25 culture flasks. Cells plated at 25 000 cells per T25 reached 100% confluency at day 6. Cells 
plated at 100 000 cells reached 100% confluency at day 5. Both cell numbers reached 40% 
confluency at day 1. Cells plated at 250 000 and 500 000 cells per T25 flask, reached 40% 
confluency already the first day. Cells plated at 250 000 reached 100% confluency at day 5, and 
cells plated at 500 000 cells reached 100% confluency at day 3. Cells plated at 500 000 cells 
per flask started to decrease in confluency the last two days of the experiment (figure 3.1.4). 
Initial Cell Seeding Slope Of Log Phase 
(x104) 
Days Defining Log 
Phase 
25 000 731 0-4 
100 000 919 0-3 
250 000 902 0-3 
500 000 1151 0-2 
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Figure 3.1.4: Progression of cell confluency per day of the second 8-day growth curve 
experiment, one curve for each cell number plated. Shows the confluency of the T25 
culture flasks behind figure 3.1.1, for the 8 days of the growth curve experiment. Cell 
confluences below 40% are referred to as “<40%”. One biological replicate. 
 
 
 
 
Reuse of culture flasks for culturing SW982 cells can help minimize the lag-phase. This is 
helpful knowledge when performing experiments with cells in culture where cell confluency and 
differentiation is crucial. 
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3.2 The SW982 Cells Express IR and IGF1R 
Insulin and Insulin-Like Growth Hormone 1 (IGF1) are two proteins with a high degree of 
homology. While IGF-1 is a known potent growth hormone, studies have shown that insulin also 
contains growth-promoting actions.[8] In order for any cell to be susceptible to growth promoting 
stimuli by either insulin or IGF1, it must express the respective receptors: insulin receptor (IR) 
and IGF-1 receptor (IGF1R). There is no published evidence on the SW982s expressing either 
of the two receptors. The aforementioned receptors were investigated by RT-qPCR analyses, 
and were found to be expressed in SW982 (figure 3.2.1). 
  
   
   100 bp                                 84 bp     86 bp 
      
   
 
 
 
 
 
500 bp 
 
Figure 3.2.1: Gel electrophoresis showing the presence of IR in untreated, subconfluent 
SW982 cells (left band 84 bp, to the right of the ladder). Gel electrophoresis showing the 
presence of IGF1R in untreated subconfluent SW982 cell (right band, 86 bp).  
 
The expected sizes of the RT-qPCR products are 84 bp for IR and 86 bp for IGF1R. A standard 
ladder (each band representing 100, 200, 300, 400, 500 bp from the top in figure 3.2.1) was 
used to determine and verify the size of each band. The gel electrophoresis can only be used 
as a qualitative verification of mRNA presence, not as a quantitative measurement of relative 
mRNA levels. 
 
Ct values of IR and IGF1R detection in subconfluent SW982 cells were assessed using RT-
qPCR. Ct values for IR were measured at cycle 26-27, and Ct values for IGF1R were measured 
at cycle 25-26. In comparison, reference gene HPRT was stable at Ct 22 throughout the 
experiment. 
 
 
 
 
 
IR IGF1R 
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3.3 [3H]AA Release in Response to Insulin Treatment in Subconfluent Cells 
The selective release of AA is initiated mainly by cPLA2α, which binds to natural membrane 
vesicles in a Ca2+-dependent manner[50], but also sPLA2s and iPLA2s are involved in AA 
release.[97, 98] Release assays with cells pre-labeled with [3H]AA  and [14C]OA may indicate 
the involvement of AA-selective or non-selective phospholipases, respectively.[52] By release 
assay, the ability of insulin to induce release of AA was measured. This was used as a method 
to determine if insulin co–induced proinflammatory activation of SW982 cells. Compared to 
untreated cells, insulin did not give any significant increase in AA release at 4, 8, 16, 24 or 48 
hours of insulin treatment (figure 3.3.1), whereas the positive control clearly did. Averages in 
figure 3.3.1 are based on 2 biological replicates, mean fold change and SD can be found in 
appendix A. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.1: Insulin did not result in a significant increase of [3H]AA release in [3H]AA and 
[14C]OA labeled SW982 cells treated with 1 µM insulin for 4, 8, 16, 24 and 48 hours, compared 
to control (set to 1). The presented results are averages of 2 biological replicates, with 3 
technical replicates each. 
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Furthermore, in dose-response experiments, different concentrations (0.3 µM, 1 µM, 3 µM) of 
insulin treatment for 48 hours did not result in any increase in AA release in SW982 cells (figure 
3.3.2). Averages in figure 3.3.2 are based on 3 biological replicates, mean fold change and SD 
can be found in appendix B. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.2: 48 hours of 0.3 µM, 1 µM and 3 µM insulin treatment in [3H]AA and [14C]OA 
labeled SW982 cells did not result in an increase in AA release, compared to control (set to 
1). The presented results are averages of 3 biological replicates, with 3 technical replicated 
each. 
 
Hence, it seems that insulin does not induce the release of AA in [3H]AA and [14C]OA pre-
labeled SW982 cells.  
 
3.4 [14C]OA Release in Response to Insulin Treatment in Subconfluent Cells 
Oleic acid (OA; 18:1n-9) is a non-essential fatty acid, which is consumed in substantial amounts 
in the typical Western diet.[38] OA and AA release has been shown to be increased by PAF in 
keratinocytes[99], and LysoPC stimulation in pre-labeled monocytes, expressing cPLA2α, sPLA2 
and group VI iPLA2.[97] Inhibitors SB204347, MAFP, BEL, PACOCF3 of sPLA2, cPLA2α/group 
VI iPLA2, cPLA2α and group VI iPLA2, respectively, have been shown to reduce release of AA 
and OA.[97, 99] Also, potent proinflammatory cytokines IL-1β[51] and TNFα[100] have been 
shown to induce release of AA.[52]  
By radioactive release assay, the ability of insulin and IL-1β to induce release of OA was 
measured in [3H]AA and [14C]OA pre-labeled SW982 cells. It is well known in the lab that IL-1β 
causes a slight reduction in OA release compared to control.[101] A non-significant trend of 
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decreased release of OA was observed for all time points. A maximum of 40% reduction in OA 
release was observed after a 4-hour treatment with insulin, compared to control (figure 3.4.1). 
Averages in figure 3.4.1 are based on 2 biological replicates, mean fold change and SD can be 
found in appendix C. 
 
 
 
Figure 3.4.1: Insulin treatment resulted in a trend of decrease of [14C]OA release in [3H]AA 
and [14C]OA labeled SW982 cells treated with 1 µM insulin for 4, 8, 16, 24 and 48 hours, 
compared to control (set to 1). The presented results are averages of 2 biological replicates, 
with 3 technical replicates each. 
 
 
A trend of decreased OA release was also observed in dose-response experiments with 0,3 µM, 
1 µM, 3 µM insulin for 48 hours (figure 3.4.2). Averages in figure 3.4.2 are based on 3 biological 
replicates, mean fold change and SD can be found in appendix D. 
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Figure 3.4.2: 48 hours of 0.3 µM, 1 µM and 3 µM insulin treatment in [3H]AA and [14C]OA 
labeled SW982 cells resulted in a decreased release of OA compared to control (set to 1).  
The presented results are averages of 3 biological replicates, with 3 technical replicates 
each. 
 
 
Even though none of our results for OA release were significantly different from the control, a 
trend of decrease in OA release in a time and concentration dependent manner was observed 
after incubation with insulin in cultured SW982 cells.  
 
3.5 [3H]AA and [14C]OA Release in Three States of Confluency 
Having shown that in subconfluent cells insulin did not evoke AA-release, and tended to inhibit 
OA-release, we next asked if these effects could be dependent on cell confluency and cell 
differentiation. In most experiments on cultured cells, cells are experimented on in a post 
confluent state. A post confluent state will mimic the natural state of most cells in vivo. By 
radioactive release assay, [3H]AA and [14C]OA release was measured in pre-labeled confluent 
and post confluent SW982 cells. 24 hours of IL-1β treatment resulted in an increase in AA 
release significantly different from control (*) and insulin (#) treated cells, in both confluent and 
post confluent SW982 synoviocytes (figure 3.5.1). 24 hours of insulin treatment did not result in 
a significant increase in AA release in confluent or post confluent cells (figure 3.5.1). 
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Figure 3.5.1: 24 hours of IL-1β treatment results in an increase in AA release, significantly 
different from control (*) and insulin treated cells (#). 24 hours of insulin treatment did not 
give a significant increase in AA release compared to control (set to 1). The presented 
results are averages of 2 biological replicates, with 3 technical replicates each. 
 
 
 
 
Similarly, OA release was measured in confluent and post confluent cells treated with IL-1β or 
insulin for 24 hours. IL-1β treatment resulted in a significant decrease in OA release in post 
confluent cells, compared to control (*) and insulin treated cells (#) (figure 3.5.2). 24 hours of 
insulin treatment resulted in a decrease (p>0.05) in OA release in both confluent and post 
confluent cells. 
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Figure 3.5.2: 24 hours of IL-1β treatment resulted in a decrease in OA release in post 
confluent cells, significantly different from control (set to 1) (*) and insulin treated cells (#). 
24 hours of insulin treatment resulted in a decrease in OA release. The results are averages 
of 2 biological replicates, with 3 technical replicates each. 
 
 
As for subconfluent cells, 24 hours IL-1β treatment in confluent and post confluent cells resulted 
in a significant increase in AA release compared to control and insulin treated cells. Also, like in 
subconfluent cells, 24 hours of insulin treatment resulted in a decrease (p<0.05) in OA release 
in confluent and post confluent cells. 
 
3.6 Insulin Treatment Increases Metabolic Activity in SW982 Cells 
One of the characteristics of an inflamed synovium in a rheumatic joint is an invasive, 
hyperplastic synovium with an abnormally high rate of proliferation.[102] Little is known about 
which extracellular stimuli increase the proliferative rate. Obesity has previously been linked to 
several conditions, like hyperinsulinemia –a compensatory response to insulin resistance.[103] 
Increased BMI is correlated with increased disease activity in RA patients.[82] Hence we asked 
if there is a link between an increased insulin level and the hyperplastic nature of the RA 
synovium? 
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In a MTT viability assay, vital enzymes catalyze MTT conversion. By MTT viability test, changes 
in metabolic activity in response to insulin were detected after 24, 36 and 48 hours of treatment. 
Fold change was measured in SW982 cells seeded at 2500, 5000, 10000, 15000 and 25000, 
compared to negative control (SF-DMEM). Results for fold change in metabolic activity after 
treatment with DMEM10%, positive control, is shown. After 24 hours of treatment, cells plated at 
2500 cells had a fold change of 1.29 (+/-0.19) for insulin treatment and 1.59 (+/-0.12) for 
DMEM10% compared to the negative control. Cells plated at 5000 cells had a fold change of 
1.16 (+/-0.09) and 1.80 (+/-0.16) for insulin and DMEM10% treatment, respectively. Cells plated 
at 10000 cells had a fold change of 1.26 (+/-0.32) for insulin and 1.70 (+/-0.09) for DMEM10% 
compared to the negative control. Cells plated at 15000 cells had a fold change of 1.17 (+/-0.13) 
and 1.57 (+/-0.04) for insulin and DMEM10% treatment, respectively. Cells plated at 25 000 
cells had an average fold change of 1.10 (+/-0.11) and 1.40 (+/-0.03) after 24 hours of insulin 
and DMEM10% treatment, respectively (figure 3.6.1). Averages in figure 3.6.1 are based on 4 
biological replicates, mean fold change and SD can be found in appendix E. 
 
 
 
 
 
 
 
 
Figure 3.6.1: Increase in metabolic activity represented as average fold change compared to 
negative control (SF-DMEM, set to 1), based on 4 biological replicates with 6 technical 
replicates each. Cells were plated at 2500, 5000, 10000, 15000 and 25 000 cells per well in 
a 96-well plate, and treated with 1.0 µM insulin or DMEM10% for 24 hours.  
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After 36 hours of insulin or DMEM10% treatment, cells plated at 2500 cells showed a fold 
change of 1.30 (+/-0.22) and 1.94 (+/-0.16) respectively. Cells plated at 5000 cells showed a 
1.26 (+/-0.26) and 2.74 (+/-0.04) fold change of increased metabolic activity after insulin and 
DMEM10% treatment, respectively. Cells plated at 10000 cells showed a fold change of 1.19 
(+/-0.22) after insulin treatment and 2.37 (+/-0.26) after DMEM10% treatment. After 36 hours of 
the aforementioned treatments, cells plated at 15000 cells per well displayed a fold change of 
1.17 (+/-0.26) and 2.06 (+/-0.06) respectively. Cells plated at 25 000 cells had an average fold 
change of 1.09 (+/-0.26) and 1.60 (+/-0.05) after 36 hours of treatment (figure 3.6.2). Averages 
in figure 3.6.2 are based on 4 biological replicates, mean fold change and SD can be found in 
appendix F. 
 
 
Figure 3.6.2: Increase in metabolic activity represented as average fold change compared to 
the negative control (SF-DMEM, set to 1), based on 4 biological replicates with 6 technical 
replicates each. Cells were plated at 2500, 5000, 10000, 15000 and 25 000 cells per well in 
a 96-well plate, and treated with 1.0 µM insulin or DMEM10% for 36 hours.  
 
 
After 48 hours of insulin or DMEM10% treatment, cells plated at 2500 cells displayed an 
average fold change of 1.44 (+/-0.20) and 3.24 (+/-0.54), respectively. Cells seeded at 5000 
cells displayed an average fold change of 1.30 (+/-0.13) and 2.81 (+/-0.19) with the same 
treatment. Changes in metabolic activity for cells seeded at 2500 and 5000 cells were 
statistically significant from control (p<0.05). Cells plated at 10000 cells per well, had an 
average fold change of 1,22 (+/-0.21) and 2.64 (+/-0.68) after 48 hours of insulin or DMEM10% 
treatment, respectively. The same treatment resulted in an average fold change of 1.20 (+/-
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0.15) and 1.80 (+/-0.09), and 1.16 (+/-0.25) and 1.76 (+/-0.22) for cells plated at 15000 and 25 
000, respectively (figure 3.6.3). Averages in figure 3.6.3 are based on 4 biological replicates, 
mean fold change and SD can be found in appendix G. 
 
 
 
Figure 3.6.3: Increase in metabolic activity represented as average fold change compared to 
the negative control (SF-DMEM, set to 1), based on 4 biological replicates with 6 technical 
replicates each. Cells were plated at 2500, 5000, 10000, 15000 and 25 000 cells per well in 
a 96-well plate, and treated with 1.0 µM insulin or DMEM10% for 48 hours. * indicates 
significance (p<0.05). 
 
 
Cells treated with 1 µM insulin for 48 hours gave an average fold change of metabolic activity of 
1.44 (+/-0.20) and 1.30 (+/-0.13) for cells plated at 2500 and 5000 cells per well, respectively. 
These values represent an average increase in metabolic activity of 44% and 30% compared to 
the control, and are the largest increases in metabolic activity in this MTT experiment, also the 
only statistically significant results. These conditions (48 hours treatment, plating of 2500 and 
5000 cells) will be examined further to pin down the perfect concentration of insulin treatment.  
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3.7 Optimizing Conditions for the MTT Viability Assay 
Based on the results from the previous MTT viability assay, cells were plated at 2500 and 5000 
cells per well in a 96-well plate, and treated with insulin for 48 hours. 3 insulin concentrations 
were used to define the most potent concentration: 3.0 µM, 1.0 µM and 0.30 µM insulin. Positive 
(DMEM10%) and negative (SF-DMEM) controls were included in the experiment.  
 
Cells plated at 2500 cells per well and treated with 3.0 µM, 1.0 µM and 0.30 µM insulin, 
displayed significant (p<0.05) increases in metabolic activity compared to control, for all insulin 
concentrations and positive control. SW982 synoviocytes seeded at 2500 cells per well and 
treated with 3.0 µM insulin displayed a fold change of metabolic activity of 1.36 (+/-0.23) 
compared to control (figure 3.7.1). Similarly, treatment with 1 µM and 0.3 µM insulin resulted in 
fold changes of 1.51 (+/-0.22) and 1.30 (+/-0.18), respectively (figure 3.7.1). The two latter 
results were also significantly different from each other. Averages in figure 3.7.1 are based on 3 
biological replicates, mean fold change and SD can be found in appendix H. 
 
 
Figure 3.7.1: Increase in metabolic activity represented as average fold change compared to 
negative control (SF-DMEM, set to 1), based on 3 biological replicates, with 6 technical 
replicates per biological replicate. Cells were plated at 2500 cells per well in a 96-well plate, 
and treated with 3.0 µM – 0.3 µM insulin or DMEM10% for 48 hours. Significant (p<0.05) 
results labeled with *. 
 
 
 
 
  * 
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Cells plated at 5000 cells per well and treated with 3.0 µM, 1.0 µM and 0.3 µM insulin for 48 
hours displayed significant increases in metabolic activity. The observed fold changes in 
metabolic activity for cells treated with 3.0 µM, 1.0 µM and 0.3 µM, were 1.21 (+/-0.15), 1.32 (+/-
0.12) and 1.29 (+/-0.10) respectively (figure 3.7.2). All of the observed changes were statistically 
significant from the controls. Averages in figure 3.7.2 are based on 3 biological replicates, mean 
fold change and SD can be found in appendix I. 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7.2: Increase in metabolic activity represented as average fold change compared to 
the negative control (SF-DMEM, set to 1), based on 3 biological replicates, with 6 technical 
replicates per biological replicate. Cells were plated at 5000 cells per well in a 96-well plate, 
and treated with 3.0 µM, 1.0 µM 0.3 µM insulin or DMEM10% for 48 hours. Significant 
(p<0.05) results labeled with *. 
 
None of the insulin concentrations used in this experiment had cytotoxic effects on the SW982 
synoviocytes. All insulin concentrations gave an increase in metabolic activity, however cells 
seeded at 2500 cells per well and treated with 1.0 µM insulin resulted in the largest increase in 
metabolic activity. For the remaining experiments using insulin stimulation, 1 µM insulin will be 
applied along with a degree of confluency corresponding to that observed at 2500 cells per 0.32 
cm2 (surface area of 1 well in a 96-well plate). 
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3.8 Flow Cytometry Could Not Validate Increased Proliferation In SW982 
Insulin has previously been described as a potent growth factor in human cell cultures, including 
human hepatic stellate cells, human skin fibroblasts and human placental cells.[104-106] Insulin 
mediates the growth promoting effects through activation of PKB and more.[12] A MTT viability 
assay can be indicative of metabolic activity and proliferation, as it measures the conversion of 
MTT to formazan salts by mitochondrial enzymes.[107] In order to determine whether the 
increase in metabolic activity observed in MTT assays were due to increased metabolic activity 
or proliferation, flow cytometry was used to determine the proportion of cells in a proliferative 
state (G2, M or S phase) and non-proliferative state (G1 phase). 
By flow cytometry cell cycle phase was determined in subconfluent SW982 synoviocytes 
stimulated with insulin. The proportion of cells in a non-proliferative state in samples stimulated 
with insulin were not different from control samples. The percentage of cells in G1 was 89.41%, 
94.08% and 84.78% for cells treated with SF-DMEM, insulin and DMEM10%, respectively. 
Likewise, the percentage of cells in G2+M+S were 10.32%, 5.92% and 15.2% for cells treated 
with SF-DMEM, insulin and DMEM10%. Cells were stimulated with 1 µM insulin for 48 hours 
(figure 3.8.1). Numbers in figure 3.8.1 are based on one biological replicate, the other 2 
replicates can be found in appendix J. 
 
 
Figure 3.8.1: Cells stimulated with 1 µM insulin for 48 hours did not have a proportion of 
cells in a non-proliferative state (G1), different from control. Cells treated with DMEM10% 
had a higher proportion of cells in a proliferative state compared to control (G2+M+S). 
Results presented in the figure are based on one experiment, with a trend representative 
for 2 other biological replicates. 
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The flow cytometry assay could not validate that the insulin-induced change observed with the 
MTT assay was due to a change in rate of proliferation. 48 hours of 1 µM insulin treatment did 
not result in a change in the proportion of cells in a non-proliferative state. 
 
 
3.9 Insulin Induces Changes in Gene Expression 
 In order to be receptive to the growth promoting effects of insulin stimuli, SW982 cells have to 
express the appropriate receptor for this kind of stimuli, the insulin receptor (IR). Also, it has 
previously been shown that the growth promoting actions of insulin, can be conducted by an 
additional receptor; the insulin-like growth factor 1 receptor (IGF1R).[108] c-Myc is a cellular 
oncogene and a marker for cell growth, proliferation, apoptosis and cellular metabolism. c-Myc 
has been shown to be regulated transcriptionally and post-transcriptionally, and mRNA levels 
have shown to be induced in quiescent rat skeletal muscle cells exposed to 3 hours of 
insulin.[109] c-fos is an early immediate proto-oncogene, with a rapidly induced transcription 
and a role in several cellular processes, like cellular growth.[110] c-fos mRNA levels have been 
shown to be induced by insulin stimulation after 15 min in rat white adipose tissue, with elevated 
mRNA levels lasting for 5 hours.[111] IL-6 is a pro-inflammatory cytokine, involved in the 
regulation of immune responses, hematopoiesis and inflammation.[112] IL-6 expression has 
been shown to be induced by insulin after 3 hours of 125 nM insulin treatment in LS14 human 
adipocytes.[113, 114] 
HPRT[115], 18S[116] and B2M[117] have been shown to be promising reference genes in cell 
culture experiments where insulin is the stimulant. 
The time-dependent, insulin-induced expression of IR, IGF1R, c-myc, c-fos and IL-6 was 
investigated with RT-qPCR in subconfluent SW982 synoviocytes. Cells were stimulated with 
insulin for 2, 4, 6, 12 and 24 hours, and change in gene expression was calculated relative to 
the square root of reference genes HPRT and B2M. 18S was excluded as a normalizing gene, 
as the 18S gene expression showed a tendency to vary with insulin incubation. 
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In this study, IR and IGF1R gene expression was significantly downregulated at 2 and 12 hours, 
and 12 hours respectively. A trend of negative regulation in response to insulin stimulation was 
observed at all time points, except for 24 hours, for both receptors (figure 3.9.1). Averages in 
figure 3.9.1 are based on 3 biological replicates, mean fold change and SD can be found in 
appendix K (IR) and L (IGF1R). 
 
 
 
 
 
 
 
 
 
 
Figure 3.9.1: Regulation of INSR and IGF1R expression after 2, 4, 6, 12 and 24 hours of 
insulin stimulation (1 µM). Fold change in mRNA expression is relative to the square root of 
reference genes HPRT and B2M, and an average of 3 biological replicates. * indicates 
significance (p<0.05) compared to control (set to 1). 
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c-Myc expression was not significantly influenced by insulin stimulation compared to control 
(figure 3.9.2). Averages in figure 3.9.2 are based on 3 biological replicates, mean fold change 
and SD can be found in appendix M. 
 
 
 
 
 
 
 
 
 
Figure 3.9.2: Regulation of c-Myc gene expression after 2, 4, 6, 12 and 24 hours of insulin 
stimulation (1 µM), compared to control (set to 1). Fold change in mRNA expression is 
relative to the square root of reference genes HPRT and B2M, and an average of 3 
biological replicates. 
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c-fos gene expression was significantly downregulated after 12 hours of insulin stimulation. A 
negative regulation of c-fos gene expression was also observed at 2 hours, all though not 
statistically significant from the control. Gene expression was leveled to the control for the 
remaining time points, 4, 6 and 24 hours (figure 3.9.3). Averages in figure 3.9.3 are based on 3 
biological replicates, mean fold change and SD can be found in appendix N. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9.3: Regulation of c-Fos gene expression after 2, 4, 6, 12 and 24 hours of insulin 
stimulation (1 µM), compared to control (set to 1). Fold change in mRNA expression is 
relative to the square root of reference genes HPRT and B2M, and an average of 3 
biological replicates. * indicates statistical significance (p<0.05) compared to normalizing 
control, set as 1. 
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A non-significant induction of 1.6 (+/-0.25) fold of IL-6 gene expression was observed after 2 
hours of insulin stimulation in SW982s compared to control. The observed trend was still 
present at 4 hours, all though less prominent. IL-6 gene expression was not altered for the 
remaining time points of insulin stimulation (figure 3.9.4). Averages in figure 3.9.4 are based on 
3 biological replicates, mean fold change and SD can be found in appendix O. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9.4: Regulation of IL-6 gene expression after 2, 4, 6, 12 and 24 hours of insulin 
stimulation (1 µM), compared to control (set to 1). Fold change in mRNA expression is 
relative to the square root of reference genes HPRT and B2M, and an average of 3 
biological replicates. 
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18S was included in this study as a third reference gene, but was found to vary too much to be 
used as a reference gene. Therefore the fold change in mRNA levels compared to the two 
reference genes HPRT and B2M, are presented in figure 3.9.5. There were no significant 
regulations of 18S gene expression, but a trend was observed, where gene expression seemed 
to be induced after 4 hours of insulin stimulation and downregulated after 12 hours of insulin 
stimulation. Averages in figure 3.9.5 are based on 3 biological replicates, mean fold change and 
SD can be found in appendix P. 
 
 
 
 
 
 
 
 
 
Figure 3.9.5: Regulation of 18S gene expression after 2, 4, 6, 12 and 24 hours of insulin 
stimulation (1 µM), compared to control (set to 1). Fold change in mRNA expression is 
relative to the square root of reference genes HPRT and B2M, and an average of 3 
biological replicates. 
 
This study may indicate a trend of downregulation of IR and IGF1R gene expression in 
response to insulin stimulation at 2, 4, 6 and 12 hours. Also, insulin was shown to induce a 
downregulation of c-Fos after 12 hours. Insulin did not affect c-Myc expression, but induced a 
trend of decreased IL-6 gene expression. Also, insulin induced variation in the expression of a 
previously accepted reference gene 18S. 
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4. Discussion 
During the 2 years the work for this master’s thesis was performed, the effect of the hormone 
insulin on SW982 cells was investigated. Several methods were utilized in order to investigate 
the effects on SW982 cells from different aspects. Arachidonic and oleic acid release assays 
were performed to investigate the time dependent effect of insulin stimulation on arachidonic 
and oleic acid release. Arachidonic acid release is mainly facilitated by cPLA2, and can 
therefore be indicative of cPLA2 activity. The release of oleic acid is facilitated by several 
enzymes, like iPLA2, sPLA2 and other lipases.[38, 98] The effect of insulin treatment on SW982 
cells was also measured by MTT assays. Because the MTT assay measures the intracellular 
conversion of 3,4,5 dimethylthiazol-2,5 diphenyl tetrazolium (MTT) to a formazan precipitate, an 
increase in the conversion can be indicative of an increase in metabolic activity or an increase 
in cell number and proliferation. In order to determine whether the effects of insulin observed 
with the MTT assay was due to an increase in metabolic activity or an increase in cell 
proliferation, flow cytometry was used to determine fraction of cells in a proliferative state.  
 
In order to investigate the effect of insulin on the expression of some proliferation genes and 
one inflammatory gene, RT-qPCR was performed on cDNA samples with primers for 8 different 
genes (among these; 3 reference genes) from different time periods of insulin stimulation.  
 
The SW982 synoviocytes utilized in these experiments were always in e subconfluent state at 
the time of treatment initiation (unless otherwise stated). Cells can be in three different states; 
subconfluent, confluent and post-confluent. This decision was made in order to mimic the 
natural, proliferative environment of the synovial lining of RA joints. 
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4.1 OA/AA Release 
AA release is primarily mediated by the arachidonyl specific phospholipase, cPLA2[50], and can 
be indicative of pro-inflammatory actions mediated through cPLA2α. AA release has previously 
been shown to be induced by several factors such as ATP, thrombin, IL-1, PAF and lysoPC.[50, 
51, 53] We have shown that the rate of which AA is released is not affected by insulin stimuli. 
However, this is not necessarily synonymous with the fact that insulin does not have pro-
inflammatory effects.  
 
In this study we show that insulin stimulation decreases the release of OA, and has no effect on 
AA release. In 2004 Oestvang et al. showed that low-density lipoprotein (LDL) stimulation of 
cultured monocytes increases the release of both AA and OA through sPLA2 activation.[118] 
Thus, this implies that the effect observed in this study by insulin on OA release, is not mediated 
by sPLA2 activation, as it does not affect AA release. Similarly, Jorgensen et al. showed in 2010 
that PAF induces the release of both AA and OA in human keratinocytes, through an iPLA2 
dependent mechanism.[99] Hence, this implies that insulin stimulated decrease in OA release is 
not mediated by iPLA2 either. The HSL also mediates free fatty acid release and is activated by 
the accumulation of cAMP, which subsequently activates protein kinase A (PKA).[119] It has 
previously been shown that insulin inhibits HSL activation through a protein kinase B (PKB) 
dependent pathway, leading to the degradation of cAMP (figure 4.1.1).[120]  
 
 
 
 
 
 
Figure 4.1.1: The activation and insulin-induced inhibition of HSL activity, by cAMP 
production and degradation, respectively. PIP2: Phosphatidylinositol-4,5-bisphosphate. 
PIP3: Phosphatidylinositol-3,4,5-trisphosphate. PDK1: Phosphoinositide-dependent Kinase 
1. PDE3B: Phosphodiesterase 3B. AMP: Adenosine Monophosphate. cAMP: Cyclic AMP. 
AC: Adenylate Cyclase. PKA: Protein Kinase A. 
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Once released from phospholipids or TDMglycerides, OA is converted to n-9 eicotrioenic acid 
(ETA) by Δ5-desaturases. ETA can inhibit the production of the pro-inflammatory LTB4s. ETA is 
a substrate for 5-lipoxygenase and is converted to LTA3, which binds to LTA4 hydrolase and 
thus inhibits the production of LTB4 from LTA4 (figure 4.1.2).[38] Inhibition of the production of 
the pro-inflammatory LTB4 can be considered anti-inflammatory actions by ETA. 
 
 
 
 
 
Figure 4.1.2: Production of LTA3 follows the release of OA. LTA3 further inhibits the 
production of pro-inflammatory LTB4. 
 
The n-3 eicopentaoenic acid (EPA; 20:5n-3) is derived from the essential fatty acid ALA, which 
is found in leafy greens, flaxseed and canola oils. The conversion of ALA to EPA is an 
extremely timely process in the human body, and the main source of EPA is through the diet 
(fish and n-3 fatty acid supplements). It is commonly known that EPA provides health benefits 
and has anti-inflammatory actions. One of the mechanisms through which EPA promotes anti-
inflammatory actions is by competing for enzymes 5-lipoxygenase and cyclooxygenase with 
their common substrate AA, leading to a decrease in the production of LTB4 and PGE2, 
respectively. The fact that ETA affects the production of the pro-inflammatory LTB4 through a 
similar mechanism as EPA, may point to similar anti-inflammatory effects of ETA. Because 
insulin inhibits the production of ETA, insulin may be labeled as pro-inflammatory. 
One major source of oleic acid is olive oil. Olive oil is a central component of the Mediterranean 
diet, which is believed to be one of the healthier dietary choices.[121] It is currently not known 
why the Mediterranean diet is so beneficial, but it could be possible that parts of the explanation 
could be found in the anti-inflammatory actions of OA. 
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It is accepted that the hormone sensitive lipase releases OA from tri-, di- and 
monoglycerides.[46] It is an established theory that insulin inhibits the hormone sensitive 
lipase.[120] It is also an established theory that the n-9 ETA inhibits the production of LTB4.[38] 
However, connecting the observed decrease in OA release with an inhibition of HSL is strictly a 
speculation. This is a hypothesis that would have to be thoroughly tested with a series of lab 
experiments. One way to do this could be to apply an inhibitor for HSL to the cell culture and 
perform the OA release experiment over again with insulin. If there was still a decrease in the 
release of OA in response to insulin, this could imply that the HSL is not responsible for the 
observed effects. Whether there is a connection between insulin stimulation and a decreased 
production of n-9 ETA is also only a speculation, which will have to be tested further. An 
enzyme-linked immunosorbant assay (ELISA) of the insulin-stimulated cells could reveal 
amounts of ETA in the cells relative to control cells. Also, an ELISA could measure whether the 
amount of LTB4 was higher in insulin treated cells, than in control cells. To summarize, several 
tests have to be performed in order to verify/reject the hypothesis presented in this chapter. A 
clarification of the speculations in this chapter, could eventually lead to a dietary advice for RA 
patients, where a decreased consumption of carbohydrates would be preferable if insulin was 
labeled pro-inflammatory. 
 
4.2 Positive Flow Cytometry Results in THP1 After Insulin Stimulation 
The RA synovium is characterized by its hyperplastic nature. The inflamed synovium hyper 
proliferates while simultaneously secreting pro-inflammatory cytokines and cartilage destructive 
agents such as MMPs. The MTT assay revealed that insulin induces increased production of 
formazan crystals in subconfluent SW982 synoviocytes. Because the flow cytometry assay 
could not confirm, it could not be concluded that the observed increase indicated hyper 
proliferation. Cells used for flow cytometry were stimulated under the exact same conditions as 
cells in the MTT assay, 48 hours of 1 µM insulin in subconfluent cells. One possible explanation 
for why the flow cytometry assay was negative might be the duration of stimulation. When a 
cellular response is observed in the form of proliferation after 48 hours, it is possible that the 
change in expression of proliferative genes and shift in cell cycle phase occurs before the actual 
proliferation, and is no longer detectable at 48 hours. Jamal Naderi, a fellow master student in 
the lab, has studied the effect of insulin in monocytes (THP1), and observed a significant 
difference in cell cycle phase between quiescent cells and insulin stimulated quiescent cells 
after 24 hours.[122] The observable difference in cell cycle phase with flow cytometry is very 
little, with only a small percent difference in cells in dormant and proliferative phases.[123] For 
one treatment, for instance insulin, a couple of percent more cells in G1 means a couple of 
percent fewer cells in the proliferative phases (G2+M+S). Hence, Naderi’s results may indicate 
that the 48-hour stimulation period used in the SW982 cells was too long, and that a potential 
difference in cell cycle phase was no longer detectable at this time.   
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One of the many enzymes activated by the insulin-signaling pathway is protein kinase B 
(PKB).[12] Activation of protein kinase B leads to the activation of several downstream signaling 
pathways, which affects the cell in different ways. Examples of cellular effects are increased 
proliferation and inhibition of apoptosis (figure 4.2.1).[12]  
 
 
Figure 4.2.1: PKB can be activated by the insulin-signaling pathway, and lead to inhibition 
of apoptosis and cell cycle promotion. 
 
 
Overexpression of constitutively activated PKB mutants promotes cellular transformation in 
many cell types, through inducing proliferation in growth-arrested cells and inhibiting apoptosis. 
This results in an artificially high rate of proliferation and cell survival, which characterizes both 
cancers and inflamed synovium. This could suggest a possible role for insulin signaling in both 
cancer and RA. PKB has previously been shown to be overexpressed in ovarian, breast and 
pancreatic cancers.[12] All of the aforementioned types of cancer have been related to 
obesity[124], which again is associated with insulin resistance and hyperinsulinemia.[124] For 
RA, DAS28 scores in RA patients increase with increasing BMI. These results may point to a 
central role for insulin in cancer and RA. In conclusion, the MTT results may be a result of 
insulin signaling through activation of PKB and inducing increased cell survival. Increased cell 
survival is not desirable in the hyperplastic synovial lining of RA joints. 
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4.3 A Trend of Downregulation of IR and IGF1R Gene Expression 
It has previously been reported that the extracellular availability of the IR is decreased in 
response to insulin stimuli, by internalization and degradation of the IR after binding of 
insulin.[125] It has also been shown that extracellular stimuli can regulate the expression of 
IR[126, 127], and that also insulin downregulates the expression of IR and accelerates IR 
degradation, in pancreatic acinar cells.[127] Insulin has also been shown to reduce the number 
of IRs on the cell surface in cultured hepatocytes, fibroblasts and fat tissue explants.[128] 
At chronically elevated levels, insulin is able to desensitize the IR through several 
mechanisms.[16]  
 
In this study, we found that IR gene expression was significantly downregulated after 2 and 12 
hours of insulin treatment. The overall trend for all time-points seemed to be downregulation of 
gene expression, except for 24 hours of insulin treatment, when the level was brought back to 
basal expression levels. One plausible explanation for the IR gene expression returning to basal 
levels at 24 hours might be that the target cell was desensitized, and the actions of insulin 
stimulation were abolished. 
 
The IGF1R signals through multiple intracellular pathways by phosphorylation of Shc and insulin 
receptor substrate (IRS) -1, -2, -3, and -4, including the PI3K, Akt and the mitogen-activated 
protein kinase (MAPK) pathways.[129, 130] Activation of the aforementioned pathways plays a 
role in different cellular events, including cell growth, differentiation, migration and survival.[129] 
However, the IR and the IGF1R are able to trigger distinct cellular responses, even though they 
are able to activate similar signaling pathways and target the same intracellular substrates.[130] 
IGF1R gene expression has been reported to be regulated by various factors including IGF-1, 
platelet derived growth factor (PDGF), estrogen and LDL, in vascular smooth muscle cells.[129] 
 
It has previously been shown that insulin can bind to the IGF1R and conduct its growth 
promoting activities through this receptor.[108] It is therefore not surprising that the same trend 
of gene regulation is observed for the IGF1R gene as for the IR gene. In this study, gene 
expression of IGF1R was found to be significantly downregulated after 12 hours of insulin 
stimulation, also the overall trend for IGF1R was a negative regulation of gene expression at 2, 
4 and 6 hours of insulin stimulation. After 24 hours of insulin stimulation, the IGF1R gene 
expression returned to basal expression levels. 
 
The fact that insulin stimulation resulted in a decreased expression of IR and IGF1R, indicates 
that the SW982 cells are amenable to insulin signaling and the cellular effects of insulin receptor 
and IGF1R pathways. The observed return to basal expression levels at 24 hours may indicate 
a desensitization of the receptors in response to insulin. The potential fact that SW982 cells are 
susceptible to the effects of insulin, means that every new discovery of insulin action in cells is a 
potential regulator of SW982 activity. 
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4.4 C-myc Gene Expression is Not Regulated by Insulin Stimulation 
C-myc is a gene previously shown to be associated with cell proliferation, growth, apoptosis and 
metabolism. C-myc is regulated both transcriptionally and post-transcriptionally, and gene 
expression has been shown to be induced after 2-3 hours of insulin stimulation in quiescent rat 
skeletal muscle cells.[109, 131] 
In this study we were not able to induce c-myc gene expression at any time-point of insulin 
incubation. In fact, it has previously been shown that insulin was unable to induce c-myc 
expression in fibroblasts, and that these fibroblasts were unable to arrest growth at low serum 
levels.[132] Fibroblasts constitutively overexpressing c-myc did not increase in cell number in 
culture, because of substantial cell death.[133] Therefore, one possible explanation to why we 
could not see an induction in c-myc gene expression in response to insulin incubation is that the 
SW982 cells were not quiescent. It is also possible that insulin did not affect the expression of 
proliferative genes. 
 
4.5 C-fos Gene Expression is Downregulated by Insulin 
C-fos is a proto-oncogene and the resulting protein, Fos, forms a dimer with Jun and binds to 
DNA-regulatory elements found in control regions of various genes. C-fos gene expression has 
been associated with cell cycle progression.[110] C-fos transcription has previously been shown 
to be rapidly induced by insulin incubation (1-2 hours) in chick embryonic lens epithelial cells, 
and is an immediate early-gene.[131] 
In this study, no induction of c-fos gene expression was observed in response to insulin 
incubation at any time-points. In fact, c-fos gene expression was significantly downregulated 
after 12 hours of insulin stimulation. 
C-fos transcription is regulated by phosphorylation of the transcription factor cAMP response 
element-binding protein (CREB)[134], which has been shown to be activated by insulin through 
a cGMP-dependent protein kinase or protein kinase G (PKG)-dependent manner.[114] Insulin 
has previously been shown to increase intracellular levels of cGMP[114], which should point to 
an induction of c-fos gene expression. 
There might be several possible explanations to why c-fos gene expression was not induced as 
previously reported. One of them being, if c-fos is a marker of cell cycle progression and our 
cells were not in total quiescence, there would not be any induction of cell cycle promoting 
genes after incubation with insulin. Also, c-fos has previously been described to be 
constitutively highly expressed in the synovial tissue of RA.[135] Perhaps, this is why an 
induction of c-fos expression was not observed in our study. It is also possible that the induction 
of c-Fos gene expression occurred before 2 hours, and that the effect had faded already at 2 
hours. Further investigations of the effect of insulin on c-Fos gene expression has to be 
conducted with RT-qPCR and shorter periods of insulin stimulation. 
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4.6 Time-dependent Trend of IL-6 Induction After Insulin Incubation 
IL-6 is a marker for low-grade inflammation, a pro-inflammatory cytokine, involved in the 
regulation of immune responses, hematopoiesis and inflammation.[112] IL-6 expression has 
previously been shown to be induced (3-fold) in response to 3 hours of 125 nM insulin, in 
human adipocytes.[114] IL-6 gene expression is induced by insulin, through the same 
mechanism of PKG-CREBP activation as c-fos gene expression.[114] 
Our study shows a time-dependent trend of non-significant induction of IL-6 gene expression 
after 2 hours (1.6 (+/-0.25) fold induction). The induction faded as the time of insulin incubation 
was lengthier, and was leveled to control after 6 hours of insulin incubation. A slight, non-
significant, decrease in IL-6 gene expression was observed after 24 hours of insulin incubation. 
In order to be able to determine the regulation of IL-6 in response to insulin in SW982 cells, 
more experiments should be conducted in order to get significant results. It is important to know 
which effects insulin has on IL-6 gene expression, as an induction/decrease of IL-6 expression 
will have pro-inflammatory/anti-inflammatory effects on the synovial environment.  
 
4.7 Regulation of 18S Gene Expression by Insulin 
Ribosomes are the catalytic and regulatory centers of protein synthesis in cells. The ribosome is 
a large RNA-protein particle consisting of two subunits, the 60S and the 40S subunit, which 
together contains about 80 proteins and ribosomal RNA (rRNA). The small subunit, 40S, 
consists of the 18S rRNA and 32 ribosomal proteins.[136] The minimally regulated 18S rRNA 
has been validated several times as a good housekeeping gene and normalizing control in RT-
qPCR experiments in various tissues and with different stimulants.[137-139] 18S rRNA has 
previously been used as a housekeeping gene in insulin stimulation experiments.[140, 141] 
No significant changes in gene expression was detected for 18S in this experiment, but a 
substantial increase in gene expression was observed after 4 hours of insulin stimulation, also a 
substantial decrease in 18S gene expression was observed after 12 hours of insulin stimulation. 
These variations in gene expression were not observed for the other housekeeping genes, 
HPRT and B2M.  
This might indicate that insulin affects the transcription of the 18S gene, and that this is no 
longer a suitable reference gene in experiments with insulin stimulation. The effects of insulin on 
18S transcription has to be investigated further in order to reach a conclusion. 
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4.8 Choice of Cell Seed Number for Growth Curves 
In order to determine the total number of cells to be seeded in each culture flask at day 0, the 
knowledge and experience of the senior researchers in the lab was exploited. Seeding cells at 5 
different numbers was supposed to cover cell density from initially too scarce to initially too 
dense. Flasks seeded with 25 000 cells were expected to exhibit difficulties with proliferation, 
which they did. Cells seeded at 25 000 cells did not reach the log-phase until day 6, which was 
5 days later than the first flasks to reach the log-phase. The hypothesis is that SW982 cells are 
dependent on direct and indirect cell-cell, and cell-extra cellular matrix (ECM) communication in 
order to initiate a proliferative state. Proteins that facilitate cell-cell communication include 
Cadherins, Selectins, Ig-like cell adhesion molecules and Integrins.[142] Proteins that facilitate 
communication between cell and ECM include Integrins and integral membrane proteoglycans 
on the cell surface, and structural glycoproteins (collagens, elastins etc) and proteoglycans in 
the ECM. Cells seeded at 25 000 cells had difficulties with initiation of proliferation, which can 
be a result of difficulties with cell-cell and cell-ECM communication. Seeding 25 000 cells in a 
new T25 culture flask is too scarce to observe a full growth curve, with 4 phases, in 8 days.  
 
Culture flasks seeded with 800 000 cells at day 0 represent the other end of the scale, reaching 
the lag-phase already at day 1, subsequently transitioning into the stationary phase at day 4. 
Flasks seeded with 800 000 cells were hypothesized to reach the stationary phase at day 1 or 2 
and subsequently transition into the decline phase at day 3 or 4, too early for this cell number to 
be ideal for observing a full growth curve with all 4 phases. This was not observed in this 
experiment. One reason why cells seeded at 800 000 cells per flask did not reach the lag-phase 
and stationary phase as rapid as hypothesized, can be due to the fact that these culture flasks 
were brand new. SW982 cells are dependent on cell-cell and cell-ECM communication in order 
to initiate proliferation, which takes some time to establish. Therefore, a second growth curve 
experiment was conducted, in the same culture flasks as used in growth curve experiment 
number 1. Indeed, here the results confirmed the initial idea that the use of used culture flasks, 
with an established network of cell-ECM proteins, reduces the lag-phase dramatically for all cell 
seedings. 
4.9 Cell Confluency Reaches 100% Before Cells Enter The Stationary Phase 
Culture flasks seeded with 500 000 cells at day 0, reached the stationary phase at day 5 in the 
first growth curve experiment. These same flasks reach 100% cell confluency at day 3, meaning 
that the number of cells increased even though there was no more available growth surface. 
This observation was accompanied by morphological changes in the cells. Cells that had just 
reached 100% confluency were the same size and shape as cells in the lesser confluency 
percentage. They had the characteristic shape of a fibroblast; a thin, oblong and elongated 
structure with a thicker center. After spending some time at 100% confluency, the cell shape 
changed to a smaller, rounder and more tightly packed cell. So, even though there was no more 
growth surface available, the cells acclimated to facilitate further cell proliferation.  
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4.10 Early log-phase entry in used culture flasks 
In growth curve experiment number 2, cells were seeded at 4 different cell numbers at day 0, in 
culture flasks previously used in growth curve number 1. No lag-phase was observed for any of 
the cell numbers seeded, as they transitioned directly into log-phase during the first 24 hours 
after seeding. Flasks seeded with 25 000 cells reached the stationary phase 2 days quicker 
than in the first experiment. This may suggest that the SW982 cells are strongly dependent on 
anchoring, and that used culture flasks have a well-established coat of anchoring proteins to 
facilitate cell-ECM communication.  
 
4.11 Decline Phase In Growth Curve Number 2 
In growth curve number 1, the decline phase was only observed at day 8 for flasks seeded with 
800 000 cells and 500 000 cells. In growth curve experiment number 2, the decline phase was 
observed already at day 7 for cells seeded at 500 000 cells. These flasks also had an 
abnormally high cell number at day 6. This could be due to an inaccurate number of cells being 
seeded at day 1, causing a delay in log-phase, or due to inaccurate counting of cells in the 
flask. Cells seeded at 25 000 cells had a slight decline in cell number already from day 4, 
though this decrease in cell number was not drastic enough to be labeled decline phase. There 
was not observed any decline phase for cells seeded at 100 000 and 250 000. These cells 
started off in the log-phase from day 0 and transitioned into the stationary phase during day 4, 
exhibiting a slight increase in cell number during the remaining days of the experiment.  
 
In growth curve experiment number 2, the first flask to reach 100% confluency was the flasks 
seeded with 500 000 cells at day 0. Flasks seeded with 500 000 cells reached 100% confluency 
at day 3 and a decline in cell confluency was observed on day 7 and 8. This pattern was 
identical to what was observed in the first experiment. By day 6 all of the flasks had reached 
100% confluency, which is very different from the confluency observed in the first experiment, 
where flasks seeded with 25 000 cells did not even reach 100% confluency. Flasks seeded with 
500 000 cells reached 100% confluency at the same pace in experiment 2 as 1, while flasks 
seeded with 25 000-250 000 cells reached 100% confluency earlier in experiment 2 compared 
to experiment 1. These results may suggest that even though flasks seeded with 500 000 cells 
have enough cells to establish cell-cell communication at once both in experiment 1 and 2, they 
still need time to settle down and attach to the growth surface. The number of cells is not the 
rate-limiting factor in this case. 
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4.12 Insulin Concentration 
Previous studies using insulin incubation in various in vitro cell cultures have reported using 
insulin concentrations ranging from 0.1 µM to 5.8 µM insulin.[114, 131, 143-146] A 
concentration of 1 µM insulin was chosen based on the fact that this concentration resulted in 
the largest increase in metabolic activity in cultured SW982 synoviocytes, and did not appear 
cytotoxic in any way. The reported levels of insulin in synovial fluid were 0.70 nmol/L and 0.202 
nmol/L, in RA and OA joints, respectively.[147] In comparison, the level of insulin in RA synovial 
fluid is 0.00041 nM and the concentration of insulin used in these tissue culture experiments are 
1000 nM.  
Insulin and c-peptide are found in the synovial fluid of both RA and OA patients.[147] Rovensky 
et al. reported in 2005 that there were no significant differences in insulin levels of plasma and 
synovial fluid, between OA and RA patients.[147] The same group, reported in 2007 that levels 
of insulin in plasma and synovial fluid are increased in RA patients in comparison with OA 
patients.[148] OA patients have been reported to have higher levels of C-peptide and insulin in 
the synovial fluid than in plasma. RA patients, on the other hand, had higher concentrations of 
C-peptide and insulin in plasma than in the synovial fluid.[149]  
 
4.13 Achieving the Same Degree of Cell Subconfluency in Every Experiment 
In the tissue culture experiments performed in this thesis, cell confluency is crucial. All cells 
should be in a similar subconfluent state. After performing the MTT viability assay, a cell 
seeding of 2500 cells per well in a 96-well plate resulted in the largest increase in metabolic 
activity. A well in a 96-well plate has a surface area of 0.32 cm2, a well in a 48-well plate is 0.95 
cm2 (used for release assays) and a 6-well plate has a growth surface of 9.5 cm2  (used for RNA 
isolation). If the experiments had been based strictly on cells per cm2 the numbers of cells 
seeded in each of the wells on the different plates would have been 7421 cells (48-well plates) 
and 74210 cells (6-well plates). But instead of seeding this number of cells, which would have 
been too scarce, 50 000 cells and 200 000 cells were seeded. Cell confluency is not only 
dependent on the number of cells seeded and the number of hours spent in the incubator, but 
also the fitness of the cells, the handling of the cells and the passage number. The higher the 
passage number is, the faster the cells tend to grow. If these cells have a rough handling before 
seeding, they tend to need more time to proliferate. Some batches of cells have a tendency to 
grow better than other. Together, these factors will determine the amount of time needed to get 
the cells to the wanted cell confluency. When the cells are stimulated they should be at a 50% 
confluency, subconfluent, where the cells only occupy 50% of the available growth surface. This 
was accomplished by closely and frequently studying the progression of cell proliferation and 
confluency with a microscope. 
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4.14 Technical Variation With MTT Viability Assays 
The MTT viability assay measures the enzymatic conversion of MTT, and the accuracy of the 
assay is dependent on an equal environment throughout the plate, accuracy of cell seeding and 
reading of optical density (OD). In order to ensure the former, cells were not seeded in the outer 
most rows and columns of the plate. These wells were filled with PBS so that temperature and 
humidity conditions were the same for all wells. In order to ensure that approximately the same 
number of cells was seeded in each well a multi channel pipet was used. Also, the 6 pipet-tips 
were checked after adsorption of cell suspension, to ensure equal volumes of suspension. Cells 
have to be seeded evenly on the surface of each well, especially since confluency is an 
important factor in these experiments. If cells are spread unevenly on the growth surface, there 
will be areas with extreme subconfluency and areas with post confluency, which will not give us 
the results we are looking for; namely cellular effects in subconfluent cells. In order to overcome 
irregular reading of OD by the OD meter, the plate was read twice (forward and backward), to 
ensure that the same wells got the same densities. Lastly, in order to overcome any bias of the 
plate or OD meter, the different stimulations were moved around randomly on the plate.  
There were no significant changes in the positive controls compared to the negative controls in 
most of the MTT viability assay, due to the fact that only two wells per experiment were 
sacrificed to positive controls, to verify that the assay had worked. 
 
4.15 Technical Variation With Release Assays 
All of the same factors regarding cellular aspects of the MTT viability assay are true for the 
release assay as well. In addition, there are technical variations specific for the release assay. 
In this assay we incorporate radioactively labeled fatty acids, AA and OA, into the cellular 
membranes of cultured cells. After incubation with radioactively labeled medium, we remove this 
and replace it with a non-labeled medium with a stimulant. We the measure the amount of 
radioactively labeled fatty acids released into the supernatant, and relate this to the amount of 
radioactively labeled fatty acids residing in the cells (lysed with NaOH). By relating the amount 
of fatty acids in the supernatant to the amount of fatty acids in the cells, we can overcome 
variations in number of cells in each well. Thus, we have to be careful to not get any cells in the 
supernatant, and vice versa. Also, it is important to collect all of the supernatant and afterwards, 
all of the lysed cells. 
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5. Conclusion 
This thesis concerns the cellular effects of insulin on cultured, subconfluent SW982 
synoviocytes. Several aspects of insulin actions were investigated, including the effect of insulin 
on metabolic activity, cellular proliferation, activation of cPLA2α and regulation of IR, IGF1R, c-
Myc, c-Fos and IL-6 gene expression. In addition, it was demonstrated that SW982 
synoviocytes express IR and IGF1R.  
 
Insulin incubation did not have any effect on AA release in subconfluent SW982 cells, 
suggesting that insulin did not activate cPLA2α under the given conditions. A trend of decreased 
OA release was observed in response to a 48-hour treatment of insulin. The underlying 
mechanism for the observed decrease is unknown, but we humbly propose a mechanism 
involving the insulin induced inhibition of hormone sensitive lipase, as a reason for the observed 
decreased release of OA. Further, the ETA-inhibited production of the pro-inflammatory LTB4 is 
presented, and as insulin decreases the release of OA, pro-inflammatory effects of insulin are 
speculated upon. If insulin could be labeled as pro-inflammatory, this could influence dietary 
advices for RA patients. Reducing the presence of a pro-inflammatory agent might potentially 
be beneficial for the disease activity of RA patients. 
 
Incubating subconfluent SW982 cells with insulin resulted in a significant increase in metabolic 
activity after 48 hours. Flow cytometry could not validate an induction of proliferation by 
identifying differences in cell cycle phase. However, if an additional experiment with flow 
cytometry on subconfluent SW982s was conducted, with a shorter period of insulin treatment as 
performed by Naderi et al, we have strong believes that this could validate the observed 
increases in metabolic activity as hyper proliferation. A possible explanation for the observed 
effects of insulin is examined, where insulin induces cell cycle promotion and inhibits apoptosis, 
through activation of PKB. This might possibly place insulin responsible for increased survival of 
synovial cells. 
 
Finally, insulin induced downregulation of IR, and the same trend was observed for IGF1R gene 
expression. Which might suggest that the SW982s are sensitive to insulin signaling through the 
IR and the IGF1R. Insulin induced no change in c-Myc expression, and induced a 
downregulation of c-fos after 12 hours. Further, insulin induced a time-dependent trend of 
increase in IL-6 gene expression. Insulin also induced variation in the expression of the 
previously accepted reference gene 18S. 
 
More tests have to be conducted in order to validate/discard the hypotheses proposed in this 
study. Including the possible pro-inflammatory actions of insulin in synovial cells and other 
tissue, mediated through inhibition of HSL. The potential for insulin to induce hyper proliferation 
and increased survival of synovial cells through activation of PKB, and the potential for insulin to 
induce expression proliferative and inflammatory genes. 
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A potential validation of insulin as an inflammatory mediator in SW982 cells, a model for 
synovitis, could lead to novel dietary advices for RA patients concerning the macronutrient 
composition of their diet. If insulin were to be labeled an initiator of hyper proliferation and 
mediator of cell survival in synovial cells, this would be valuable information for physicians and 
RA patients in lowering the disease activity and possibly slowing disease progression.  
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Appendix 
 
A. All biological replicates (n=2) for the representative experiment in figure 3.3.1. 
 
Table A.1 Mean AA release fold changes after insulin incubation for 4, 8, 16, 24 and 48 hours. * 
indicates results significantly different from control (p<0.05), which was set to 1. 
 
 
 
 
B. All biological replicates (n=3) for the representative experiment in figure 3.3.2. 
 
Table B.1 Mean AA release fold changes after insulin incubation for 48 hours, three different 
insulin concentrations. * indicates results significantly different from control (p<0.05), which was 
set to 1. 
 
 
 
 
 
 
 
 
 
 
Treatment 48h 
0.3 µM INS 0.82 
±SD 0.02 
1 µM INS 0.86 
±SD 0.03 
3 µM INS 0.78 
±SD 0.17 
IL-1β 10 ng/mL 2.31* 
±SD 0.06 
Treatment 4h 8h 16h 24h 48h 
1 µM INS 0.70 0.83 0.87 0.84 0.86 
±SD 0.09 0.10 0.06 0.03 0.03 
IL-1β 10 ng/mL 2.22* 4.90* 3.71* 3.22* 2.31* 
±SD 0.17 0.14 0.32 0.20 0.06 
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C. All biological replicates (n=2) for the representative experiment in figure 3.4.1. 
 
Table C.1 Mean OA release fold changes after insulin incubation for 48 hours, three different 
insulin concentrations.  
 
 
 
 
D. All biological replicates (n=3) for the representative experiment in figure 3.4.2. 
 
Table D.1 Mean OA release fold changes after insulin incubation for 48 hours, three different 
insulin concentrations.  
 
 
 
 
 
 
 
 
 
 
 
Treatment 4h 8h 16h 24h 48h 
1 µM INS 0.56 0.69 0.77 0.83 0.78 
±SD 0.06 0.05 0.08 0.14 0.06 
IL-1β 10 ng/mL 0.89 1.65 1.52 1.35 0.89 
±SD 0.08 0.09 0.12 0.11 0.16 
Treatment 48h 
0.3 µM INS 0.78 
±SD 0.04 
1 µM INS 0.78 
±SD 0.06 
3 µM INS 0.74 
±SD 0.06 
IL-1β 10 ng/mL 0.89 
±SD 0.16 
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E. All biological replicates (n=4) for the representative experiment in figure 3.6.1. 
 
Table E.1 Mean fold changes of metabolic activity measured by MTT assay, after insulin 
incubation for 24 hours. Different number of cells seeded. 
Number of Cells Seeded 24h 
2500 1.29 
±SD 0.19 
5000 1.16 
±SD 0.09 
10 000 1,26 
±SD 0.33 
15 000 1.18 
±SD 0.13 
25 000 1.10 
±SD 0.11 
  
 
 
 
F. All biological replicates (n=4) for the representative experiment in figure 3.6.2. 
 
Table F.1 Mean fold changes of metabolic activity measured by MTT assay, after insulin 
incubation for 36 hours. Different number of cells seeded. 
Number of Cells Seeded 36h 
2500 1.31 
±SD 0.22 
5000 1.26 
±SD 0.27 
10 000 1,19 
±SD 0.23 
15 000 1.18 
±SD 0.26 
25 000 1.09 
±SD 0.27 
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G. All biological replicates (n=4) for the representative experiment in figure 3.6.3. 
 
Table G.1 Mean fold changes of metabolic activity measured by MTT assay, after insulin 
incubation for 48 hours. Different number of cells seeded. * indicates results significantly 
different from control (p<0.05), which was set to 1. 
Number of Cells Seeded 48h 
2500 1.44* 
±SD 0.20 
5000 1.31* 
±SD 0.13 
10 000 1,22 
±SD 0.21 
15 000 1.20 
±SD 0.16 
25 000 1.16 
±SD 0.26 
 
 
 
 
H. All biological replicates (n=3) for the representative experiment in figure 3.7.1. 
 
Table H.1 Mean fold changes of metabolic activity measured by MTT assay, after incubation 
with different concentration of insulin for 48 hours. Cells seeded at 2500 cells per well. * 
indicates results significantly different from control (p<0.05), which was set to 1. 
Treatment 48h 
0.3 µM INS 1.30* 
±SD 0.18 
1 µM INS 1.51* 
±SD 0.22 
3 µM INS 1.36* 
±SD 0.23 
DMEM10% 3.04* 
±SD 0.31 
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I. All biological replicates (n=3) for the representative experiment in figure 3.7.2. 
 
Table I.1 Mean fold changes of metabolic activity measured by MTT assay, after incubation with 
different concentration of insulin for 48 hours. Cells seeded at 5000 cells per well. * indicates 
results significantly different from control (p<0.05), which was set to 1. 
Treatment 48h 
0.3 µM INS 1.29* 
±SD 0.10 
1 µM INS 1.32* 
±SD 0.12 
3 µM INS 1.22* 
±SD 0.15 
DMEM10% 2.85* 
±SD 0.41 
 
 
 
J. Each of the biological replicates, where number 1 is presented in figure 3.8.1. 
 
Table J.1 Percent of cells in G1 and G2+S+M for each of the biological replicates from the flow 
cytometry experiment. Biological replicate number 2. 
Treatment G1 G2+M+S 
SF-DMEM 89.41 10.32 
1 µM INS 94.08 5.92 
DMEM10% 84.78 15.2 
 
 
 
 
Table J.2 Percent of cells in G1 and G2+S+M for each of the biological replicates from the flow 
cytometry experiment. Biological replicate number 2. 
Treatment G1 G2+M+S 
SF-DMEM 78.34 16.32 
1 µM INS 79.84 13.74 
DMEM10% 65.65 22.14 
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Table J.3 Percent of cells in G1 and G2+S+M for each of the biological replicates from the flow 
cytometry experiment. Biological replicate number 3. 
Treatment G1 G2+M+S 
SF-DMEM 85.12 13.65 
1 µM INS 80.19 10.87 
DMEM10% 83.6 15.93 
 
 
 
 
K. All biological replicates (n=3) for the representative experiment in figure 3.9.1. 
 
Table K.1 Mean fold changes of IR mRNA levels, after incubation with insulin for 2, 4, 6, 12 and 
24 hours. * indicates results significantly different from control (p<0.05), which was set to 1. 
Treatment 2h 4h 6h 12h 24h 
1 µM INS 0.51* 0.67 0.72 0.38* 0.95 
±SD 0.14 0.11 0.14 0.19 0.24 
 
 
 
L. All biological replicates (n=3) for the representative experiment in figure 3.9.2. 
 
Table L.1 Mean fold changes of IGF1R mRNA levels, after incubation with insulin for 2, 4, 6, 12 
and 24 hours. * indicates results significantly different from control (p<0.05), which was set to 1. 
Treatment 2h 4h 6h 12h 24h 
1 µM INS 0.41 0.62 0.55 0.26* 1.01 
±SD 0.33 0.13 0.42 0.16 0.19 
 
 
 
M. All biological replicates (n=3) for the representative experiment in figure 3.9.3. 
 
Table M.1 Mean fold changes of c-Myc mRNA levels, after incubation with insulin for 2, 4, 6, 12 
and 24 hours.  
Treatment 2h 4h 6h 12h 24h 
1 µM INS 1.01 1.06 1.13 0.80 0.85 
±SD 0.20 0.19 0.14 0.19 0.10 
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N. All biological replicates (n=3) for the representative experiment in figure 3.9.4. 
 
Table N.1 Mean fold changes of c-Fos mRNA levels, after incubation with insulin for 2, 4, 6, 12 
and 24 hours. * indicates results significantly different from control (p<0.05), which was set to 1. 
Treatment 2h 4h 6h 12h 24h 
1 µM INS 0.54 1.21 1.20 0.39* 0.91 
±SD 0.28 0.38 0.27 0.18 0.11 
 
 
 
O. All biological replicates (n=3) for the representative experiment in figure 3.9.5. 
 
Table O.1 Mean fold changes of IL-6 mRNA levels, after incubation with insulin for 2, 4, 6, 12 
and 24 hours.  
Treatment 2h 4h 6h 12h 24h 
1 µM INS 1.6 1.29 1.06 0.91 0.60 
±SD 0.25 0.28 0.14 0.66 0.07 
 
 
P. All biological replicates (n=3) for the representative experiment in figure 3.9.6. 
 
Table P.1 Mean fold changes of 18S mRNA levels, after incubation with insulin for 2, 4, 6, 12 
and 24 hours.  
Treatment 2h 4h 6h 12h 24h 
1 µM INS 0.95 1.41 0.99 0.35 1.06 
±SD 0.04 0.79 0.15 0.28 0.47 
 
 
 
 
 
 
 
 
 
